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ABSTRACT 
Impact of Diabetes Complications on Breast Cancer Screening, Diagnosis, and 
Prognosis among Elderly Women with Pre-existing Diabetes Using the SEER-
Medicare Dataset 
 
Ebtihag O. Alenzi  
Diabetes has been linked to lower rates of breast cancer (BC) screening, late stage of BC at 
diagnosis, and high mortality of incident BC. Up to date, no study has investigated the influence 
of diabetes complications and their severity on this linkage. The aims of the study were to 
explore the association between severity of diabetes-related complications and persistence with 
screening mammography in elderly women with diabetes; to check the association of diabetes 
complications severity with stage of BC at diagnosis in elderly women with incident BC and pre-
existing diabetes; and to assess the effect of diabetes-related complications severity on all-cause 
mortality within 3 years of a BC diagnosis in elderly women with pre-existing diabetes. Aim 1 
was conducted using the 5% random sample of linked Surveillance, Epidemiology, and End 
Results (SEER)-Medicare data among 16,526 elderly women with diabetes who were free of 
cancer during the years 2002 to 2008. Aim 2 was conducted using SEER-Medicare data among 
7,729 elderly women with incident BC and pre-existing diabetes during the years 2004–2011. 
Aim 3 was conducted among a cohort of women age ≥ 67 years diagnosed with BC in 2007 to 
2011 and pre-existing diabetes (N = 4,307). Chi-square tests were used to examine the significant 
differences in characteristics of the study cohorts by persistence with screening mammogram, 
stage of BC at diagnosis, and three-year mortality, respectively. Multinomial logistic regressions 
were used to check the association of diabetes complications severity with persistence with 
screening mammography and stage of BC at diagnosis. Hazards ratios (HR) of all-cause 
mortality within 3 years of BC diagnosis was estimated using unadjusted and adjusted Cox 
proportional hazards models to compare time to death based on diabetes complications severity 
index (DCSI). Overall, having high severity of diabetes complications was significantly 
associated with a decrease in the likelihood of receiving breast cancer screening as compared to 
those without diabetes complications. Among elderly women with diabetes, those with a DCSI ≥ 
5 were significantly less likely to use screening mammogram (either persistent use (odds ratio 
(OR) = 0.08; 95% confidence intervals (CI) = 0.07-0.10) or non- persistent use (OR = 0.32; 95% 
CI = 0.28-0.37)), as compared to those without diabetes complications. Also, the severity of 
diabetes complications was no longer an independent predictor of BC stage II or advanced stage 
(III/IV) at diagnosis. However, women with DCSI =2 were significantly 26% more likely to be 
diagnosed at stage I (versus stage 0) of BC at diagnosis as compared to those without diabetes 
complications (OR = 1.26; 95% CI = 1.03-1.53). In addition, severity of diabetes complication 
was significantly associated with all-cause mortality within three years of BC diagnosis. Women 
with a DCSI =1, DCSI =2, and DCSI ≥3 had 34% (hazard ratios (HR) = 1.34; 95% CI = 1.02-
1.75), 69% (HR = 1.69; 95% CI = 1.39-2.05), and 124% (HR = 2.24; 95% CI = 1.86-2.70) 
increased risk of death within 3 years after BC diagnosis as compared to those without diabetes 
complications. The association between diabetes and worse BC outcomes could be predicted by 
severity of diabetes complications since this severity has negative consequences on screening 
mammography, diagnosis, and prognosis. 
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INTRODUCTION 
Diabetes mellitus (DM) is a major public health issue that has grown worldwide in 
conjunction with aging of populations, urbanization, and unhealthy behaviors (Shikata, 
Ninomiya, & Kiyohara, 2013). According to the American Diabetes Association (ADA), the 
annual  incidence of diabetes in the US was 1.7 million in 2012 (Diabetes.org, 2015). It is 
associated with many complications and comorbidities that are responsible for impairing quality 
of life and increasing mortality in affected individuals (Zimmet, Alberti, & Shaw, 2001). About 
one third of  individuals with DM are elderly with ages ≥ 65 year who are disproportionately at 
the highest risk of developing complications due to the potentially longer duration of disease and 
aging process (Corriere, Rooparinesingh, & Kalyani, 2013).    
A large body of literature suggests that individual with diabetes have a significantly 
higher risk of cancer than those without diabetes (Barone et al., 2008; Giovannucci et al., 2010; 
Lam et al., 2011; Liao et al., 2011; Lipscombe et al., 2008; Tudzarova & Osman, 2015; Vigneri 
et al., 2009).  One of the most common types of cancer is breast cancer (BC) with about 1.7 
million new cases worldwide in 2012 and more than 50% of cases occurring in women aged ≥65 
years ( wcrf.org, 2015; Muss, 2010).                                                                                                                                                                                                                                                                                                                                                                                                               
Many epidemiological studies have showed that women with DM have a significantly 
higher risk of incident breast cancer than women without diabetes (Boyle et al., 2012; Larsson, 
Mantzoros, & Wolk, 2007; Liao et al., 2011). A meta-analysis by Boyle et al., showed that the 
risk of BC in women with type 2 diabetes has increased by 27%, even after controlling for body 
mass index (BMI) (Boyle et al., 2012). Other studies demonstrated that the prevalence of pre-
existing DM among incident BC was from 16% to 20% (Bao et al., 2015; Tammemagi et al., 
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2005), especially among postmenopausal women (Cleveland et al., 2012). A study by Cleveland 
et al., showed that postmenopausal women with DM are at higher risk of developing incident 
breast cancer than those without DM (Cleveland et al., 2012). Taken together, these studies 
reveal that DM is a well-established independent risk factor for breast cancer.   
Diabetes and BC Screening 
Since diabetes is associated with increased risk of BC, regular BC screenings for women 
with DM is essential. The American College of Obstetricians and Gynecologists (ACOG) 
guideline strongly recommends starting regular annual mammography screening for women at 
age 40 years (ACOG, 2016). The American Cancer Society (ACS) recommends starting annual 
mammogram screening at age 45 years, and women can switch to biennial mammogram 
screening at age 55 years (Oeffinger et al., 2015). However, the US Preventive Services Task 
Force (USPSTF) recommends biennial screening mammography for women aged 50-74 years 
(Table 1) ( USPSTF, 2016).    
Studies have been shown that having regular BC screening decrease the likelihood of late 
stage diagnosis and mortality from incident BC (McCarthy et al., 2000; Vyas, Madhavan, & 
Sambamoorthi, 2014). A previous study by McCarthy et al., found that elderly women who had 
regular screening mammography were diagnosed with an earlier stage of disease and had lower 
mortality rates as compared to non-users of screening mammography (McCarthy et al., 2000). 
Also, a recent study by Vyas et al. showed that women with persistent mammography screening 
were more likely to be diagnosed at earlier stages of BC as compared to non-persistent women or 
non-users  (Vyas et al., 2014).  
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Although regular screening mammography has been shown to reduce morbidity and 
mortality due to breast cancer, studies have shown lower rates of BC screening use among 
elderly women with DM as compared to those without DM (Beckman et al., 2001; Fleming, 
Love, & Bennett, 2011; Lipscombe, Hux, & Booth, 2005; Luo et al., 2015; McBean & Yu, 
2007). A study by Lipscombe et al. found that despite frequent primary health care visits, women 
with DM were significantly less likely to have a biennial mammogram than women without 
diabetes (Lipscombe et al., 2005). Another study among women with DM in Kentucky found 
that women with diabetes were half as likely to have regular screening mammography as 
compared to those without diabetes (Fleming et al., 2011). Lipscombe et al. indicated that the 
complexity of diabetes care could compete with the provision of women's preventive care 
services (Lipscombe et al., 2005). Further, a recent study showed that women who had diabetes 
for more than two years have lower rates of BC screening as compared to those without DM 
(Sanderson et al., 2014). This could explain the impact of diabetes duration on persistence with 
BC screening among women with DM. However, persistence with BC screening among women 
with DM could be affected by other diabetes-related factors, including diabetes severity and 
diabetes-related complications. 
Diabetes and BC Diagnosis   
In addition to lower rates of screening mammography use, the literature also indicated 
that women with pre-existing DM were more likely to be diagnosed with advanced stages of BC 
as compared to those without DM  ( Lipscombe et al., 2015; Luo et al., 2015; van de Poll-Franse 
et al., 2007). One study by Luo et al., showed that women with DM were more likely to be 
diagnosed with advanced stage of BC as compared to those without DM (Luo et al., 2015). A 
study conducted among Canadian women with BC showed that women with diabetes were 21 % 
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and 16% more likely to be diagnosed with Stage III and Stage IV of BC, respectively, than Stage 
I. (Lipscombe et al., 2015). This associated was significant even after controlling for 
mammogram use ( Lipscombe et al., 2015).   
DM and BC Prognosis  
The above findings may suggest that women with diabetes are predisposed to developing 
more aggressive BC, which may contribute to higher cancer mortality. Many studies have found 
that among women with BC, DM was associated with 40% higher mortality rate then women 
without DM (Lipscombe et al., 2008; Luo et al., 2015; Verlato et al., 2003). One study conducted 
among a cohort of women in United Kingdom found that women with BC and diabetes had a 
higher risk of all-cause mortality as compared to those without diabetes (Redaniel et al., 2012). 
Among Asian patients with early stage BC, DM was an independent predictor of lower BC 
survival and overall survival rates (Chen et al., 2012). Another prospective cohort study provided 
additional evidence that that pre-existing DM increases the risk of all-cause total mortality 
among women with BC, but it was not associated with increased risk of breast cancer-specific 
mortality (Luo et al., 2014). Thus, a careful attention should be paid to pre-existing DM and its 
related factors that contribute to this risk among incident BC.  
Shared Risk Factors in Diabetes & BC 
In general, there are common factors that could lead to diabetes and BC. Women with 
DM are more likely to have factors related to delayed diagnosis and high mortality rates from 
incident BC (Luo et al., 2015). In fact, women with DM are more likely to be obese, older, and 
have more chronic comorbidities, compared to those without DM (Garg et al., 2014; 
Giovannucci et al., 2010; Vona-Davis & Rose, 2012; Zanders et al., 2013). Other studies showed 
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older women with diabetes had a greater risk of developing BC than younger women with DM 
(VanderWalde & Hurria, 2012; Verhaeghe, 2009).  However, there are other potential factors 
closely related to DM that may explain the late stage diagnosis and worse prognosis of incident 
BC among women with pre-existing DM.  
Potential Factors Contributing to the Association between Diabetes & BC 
One main factor that may contribute to the association between DM and BC is 
dysregulation in insulin and steroid hormones. Hyperinsulinemia and steroid hormonal changes 
commonly occur in women with DM as part of its pathophysiological process and are considered 
to be potentially carcinogenic conditions for the breast (Salpeter et al., 2006). Insulin resistance, 
hyperinsulinemia, and chronic inflammatory factors in DM are strongly associated with BC 
(Handelsman et al., 2013; Sun & Kashyap, 2011). These changes in DM could become worse 
during menopause, and thereby make a woman with DM at a higher risk of having BC after 
menopause (Ding et al., 2007; Golden et al., 2007; Key et al., 2002; Verhaeghe, 2009). During 
menopause, women with DM are exposed to a sudden hypersecretion of androgen and estrogen 
hormones, and the boost of these hormones secretion in women with DM promotes cancer cells 
growth (Ding et al., 2006; Ding et al., 2007; Golden et al., 2007). One study revealed that DM 
was associated with a 20-25% increase in  BC risk, mainly hormone-receptor-positive cancers 
(Larsson et al., 2007). In this type of hormone-receptor-positive cancer, cancer cells have 
receptors for estrogen or progesterone, so they are called either estrogen-receptor-positive (ER+) 
or progesterone-receptor-positive (PR+). These hormones send signals to cancer cells to enhance 
their proliferation ( Breastcancer.org, 2015). Thus, these cancer-related mechanisms among 
elderly women with DM could synergistically act to promote BC development in advanced 
stages and to worsen the prognosis of incident BC (van de Poll-Franse et al., 2007).   
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In addition to insulin resistance and dysregulation of steroid hormones, DM could worsen 
the outcomes of BC treatment. Therefore, physicians may need to modify BC treatment for 
women with DM. In a systematic review by Peairs et al., three studies demonstrated that patients 
with BC and diabetes received modified breast cancer treatment as compared to those without 
diabetes (Peairs et al., 2011; Srokowski et al., 2009; van de Poll-Franse et al., 2007; Yancik et 
al., 2001). Van de Poll-Franse et al, showed that patients with diabetes and breast cancer were 
more likely to receive surgery and/or hormonal therapy, but less likely to receive chemotherapy 
and/or radiotherapy as compared to women without diabetes (van de Poll-Franse et al., 2007). 
The study conducted by Srokowski et al found that women with BC and DM were less likely to 
receive anthracyclines and taxanes as compared to women without DM (Srokowski et al., 2009). 
This data begs the question “why”. What were the author explanations for the differential 
treatment of women with DM and BC? This discrepancy needs to be further expanded for the 
reader.  
Pre-existing diabetes is also contraindicated with some medications and therapies of BC, 
thus presenting certain challenges that make cancer treatment decisions difficult and 
complicated. Previous studies showed that pre-existing DM predisposes women with BC to a 
higher risk of a chemotherapy-related toxicity as compared to those without pre-existing DM 
(Peairs et al., 2011; Psarakis, 2006; Srokowski et al., 2009). Thus, women with BC and pre-
existing DM are usually less likely to receive chemotherapy as compared to those without DM. 
Two studies have shown that women with DM were less likely to receive chemotherapy during 
the six months that follow a BC diagnosis and had higher all-cause mortality than those without 
DM (Srokowski et al., 2009; van de Poll-Franse et al., 2007). Furthermore, women with diabetes 
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who underwent cancer surgery were more likely to die in the month following their operations 
than those who have cancer but without diabetes ( hopkinsmedicine.org, 2016).   
Therefore, all the above-mentioned factors could predict a worse prognosis of incident 
BC among women with pre-existing diabetes.   
The Role of Diabetes-related Complications Severity      
As was discussed above, there are many factors related to the association between 
diabetes and BC. However, studies have not adjusted for diabetes severity. We do not know 
whether the presence of diabetes (controlled) or the severity of diabetes (uncontrolled) and its 
complications contribute to lower screening, advanced stage at diagnosis, and poorer prognosis 
for breast cancer. Therefore, we need to examine the independent role of diabetes severity on BC 
screening, diagnosis and prognosis.  
The main significant indicators of diabetes severity are diabetes-related complications 
(Hogan, Dall, & Nikolov, 2003; Selby et al., 1997; Simon et al., 2005; Tomlin et al., 2006). The 
most frequent diabetes-related complications are cardiovascular diseases and atherosclerosis, and 
the main troublesome complications in the elderly are heart and kidney insufficiencies (Chentli 
et al., 2015). These complications could exacerbate chemotherapy-induced toxicity and worsen 
cancer symptoms (Psarakis, 2006; Malik et al., 2016; Morsy & Heeba, 2016; Volkova & Russell, 
2011).  
Further, research has indicated that diabetes complications are independent predictors of 
hospitalization and mortality among individuals with DM (Hogan et al., 2003; Selby et al., 1997; 
Simon et al., 2005; Tomlin, Dovey, & Tilyard, 2008; Tomlin et al., 2006). Diabetes 
complications account for more than 35% of the health care utilizations for individuals with 
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diabetes (Hogan et al., 2003). Thus, an indicator, the diabetes complications severity index 
(DCSI), was developed to capture the severity of illness and care requirements (Young et al., 
2008; Rosenzweig et al., 2002). This indicator was first developed by Young and colleagues to 
include 7 categories of diabetes complications: cardiovascular disease, nephropathy, retinopathy, 
peripheral vascular disease, cerebrovascular, neuropathy, and metabolic complications (Young et 
al, 2008), and theses complications were identified using laboratory data and International 
Classification of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM) diagnosis code to 
represent gradations of the diabetes complications severity (Young et al., 2008). The index for 
each complication was categorized into 2 or 3 levels (no abnormality = 0, some abnormality = 1, 
and severe abnormality = 2), based on the presence and severity of the complication. The indices 
of all complications were added together to get the DCSI which is a 13-point scale with a range 
of 0-13. Using this scale, Wu et al found that compared to patients without complications (DCSI 
=0), those with more complications (higher DCSI score) had an increased risk of higher 
healthcare utilization (Wu et al., 2012).  
Need for the Study  
Since DM has a complex relationship with BC, many researchers have emphasized the 
need for well-designed studies to include a comprehensive list of potential factors that may 
contribute to this relationship (Bakhru, Buckanovich, & Griggs, 2011; Vigneri et al., 2009).    
Recent studies have confirmed the association between DM and BC (Boyle et al., 2012; 
Cleveland et al., 2012; Giovannucci et al., 2010; Lam et al., 2011; Larsson et al., 2007; Liao et 
al., 2011; Redaniel et al., 2012; Shikata et al., 2013; Sun & Kashyap, 2011; Tudzarova & Osman, 
2015; Vigneri et al., 2009). Others studies have demonstrated the impact of DM on lower rates of 
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screening mammography use (Beckman et al., 2001; Fleming et al., 2011; Lipscombe et al., 
2005; McBean & Yu, 2007; Sanderson et al., 2014), later stage diagnosis of BC ( Lipscombe et 
al., 2015), and BC mortality ( Bao et al., 2015; Barone et al., 2008; Chen et al., 2012; Cleveland 
et al., 2012; Lipscombe et al., 2008; Luo et al., 2015; Luo et al., 2014; Peairs et al., 2011; 
Redaniel et al., 2012; Srokowski et al., 2009; van de Poll-Franse et al., 2007; Verlato et al., 
2003). While most of the previously conducted studies have confirmed the significant influence 
of DM on BC spectrum of care (prevention, diagnosis, and prognosis), no study yet has 
examined the independent role of diabetes-related complications on this association, controlling 
for other possible factors (e.g. other comorbidities, diabetes medications, access to care…etc.) 
that could confound this association.  
Therefore, considering the prevalence of pre-existing DM with incident BC and the high 
burden of diabetes-related complications among elderly women, it is prudent to consider how the 
severity of diabetes complications impacts the BC screening, diagnosis and prognosis using 
DCSI. Using the linked Surveillance, Epidemiology and End-Results (SEER)-Medicare data 
which represents a large population of elderly in the US, we will determine the independent 
impact of diabetes-related complication(s) on BC spectrum of care among elderly women with 
DM in US.     
Bearing these thoughts in mind, this study has three specific aims: 
Aim 1: To investigate the association between the severity of diabetes complications and 
persistence with BC screening (mammogram) among elderly women with pre-existing DM.  
Aim 2: To determine the association of the severity of diabetes complications with stage of BC 
at diagnosis among elderly women with pre-existing DM.       
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Aim 3:  To explore the impact of the severity of diabetes complications on all-cause mortality 
among elderly women with incident BC and pre-existing DM.  
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GYNE: gynecological. ACS: American Cancer Society. USPSTF: US Preventive Services Task 
Force. ACOG: American   College of Obstetricians and Gynecologist 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1 
 The American Guidelines Recommendations for Breast Cancer Screening 
 Guideline Age group Frequency  References 
Mammogram     
 ACS 45-54 Annual (Oeffinger et al., 2015) 
  55 and older Biennial  (Oeffinger et al., 2015) 
 USPSTF 50-74 Biennial (Siu, 2016) 
 ACOG 40 and older Annual (ACOG, 2016) 
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ABSTRACT 
Objective: To determine whether there is an association between the severity of diabetes 
complications using the diabetes complications severity index (DCSI) and persistence with 
screening mammography among elderly women with diabetes Mellitus (DM) after controlling 
for all covariates that may mediate this association.     
Methods: This was a retrospective study using a 5% random sample of linked Surveillance, 
Epidemiology, and End Results (SEER)-Medicare data of 16,526 elderly women with DM who 
were free of cancer during the years 2002 to 2008. Chi-square tests were used to test for 
significant differences in characteristics among the three groups based on persistence with 
screening mammography. The expanded Andersen behavioral model was used to guide the 
selection of variables that could influence persistence with screening mammography. 
Multinomial logistic regressions were used to examine unadjusted and adjusted association 
between the severity of diabetes complications and persistence with screening mammography 
controlling for predisposing factors (race and age), enabling factors (annual visits to primary care 
providers), need factors (comorbid conditions), and external environmental factors (regions and 
metropolitan status).   
Results: Overall, presence and severity of diabetes complications was significantly associated 
with screening mammography use (either persistent or non-persistent use). Among elderly 
women with DM, those with DCSI=1, DCSI=2, DCSI=3, DCSI=4, and DCSI ≥ 5 were 
significantly 23% (odds ratio (OR) = 0.77; 95% confidence intervals (CI) = 0.68-0.89), 46% (OR 
= 0.54; 95% CI = 0.48-0.61), 66% (OR = 0.34; 95% CI = 0.29-0.41), 79% (OR = 0.21; 95% CI = 
0.17-0.25), and 92% (OR = 0.08; 95% CI = 0.07- 0.10) less likely to be persistent with screening 
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mammography, respectively,  as compared to those without diabetes complications after 
controlling for predisposing factors, enabling factors, need factors, health behaviors, and external 
environmental factors.   
Conclusions: Using a nationally representative linked data of elderly women with DM, this 
study found that as the severity of diabetes complications increases, persistence with screening 
mammography decreases among elderly women with DM. Tailored diabetes educations 
programs and new strategies that target primary care physicians, caregivers, and patients are 
essential to raise awareness about the importance of breast cancer screening for elderly women 
with diabetes complications who are high-risk patients in term of poor persistence with BC 
screening.      
Keywords: Diabetes complications; breast cancer screening; mammography; persistence; 
comorbidity 
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INTRODUCTION 
A growing body of literature suggests that diabetes mellitus (DM) is a well-established 
independent risk factor for breast cancer (BC) (Boyle et al., 2012; Cleveland et al., 2012; 
Giovannucci et al., 2010; Lam et al., 2011; Larsson, Mantzoros, & Wolk, 2007; Liao et al., 2011; 
Redaniel et al., 2012; Shikata, Ninomiya, & Kiyohara, 2013; Sun & Kashyap, 2011; Tabassum, 
Mahmood, & Faheem, 2016; Tudzarova & Osman, 2015; Vigneri et al., 2009). A meta-analysis 
by Boyle et al., showed that DM increased the risk of BC by 27% as compared to women 
without DM (Boyle et al., 2012). Another study by Cleveland et al., showed that women with 
DM are at a significantly higher risk (35%) of developing incident BC as compared to those 
without DM (Cleveland et al., 2012). A recent study conducted in Pakistan showed that women 
with diabetes had about five times more odds of developing BC than those without diabetes 
(Tabassum et al., 2016). 
Since diabetes is strongly associated with the risk of developing BC among women, 
persistence with BC screenings for women with DM is essential. The American College of 
Obstetricians and Gynecologists (ACOG) guideline strongly recommends starting regular annual 
mammography screening for women at age 40 years (ACOG, 2016). The American Cancer 
Society (ACS) recommends starting annual mammogram screening at age 45 years, and women 
can switch to biennial mammogram screening at age 55 years (Oeffinger et al., 2015). Thus, 
elderly women who aged ≥ 65 years must have either annual or biennial mammogram screening 
to decrease the likelihood of having BC diagnosis and mortality from incident BC (McCarthy et 
al., 2000; Vyas, Madhavan, & Sambamoorthi, 2014). A recent cohort study by Vyas et al. 
showed that elderly women with persistent screening mammography were more likely to be 
diagnosed at earlier stages of BC as compared to non-persistent women (Vyas et al., 2014).  
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Although regular screening mammography is very important with many benefits, studies 
have shown a lower rates of screening mammography use among elderly women with DM as 
compared to those without DM (Beckman et al., 2001; Fleming, Love, & Bennett, 2011; 
Lipscombe et al., 2015; Lipscombe, Hux, & Booth, 2005; Luo et al., 2015; McBean & Yu, 
2007). Studies found that women with DM were significantly less likely to have screening 
mammography than women without diabetes although women with diabetes had more frequent 
primary health care visits as compared to those without diabetes (Lipscombe et al., 2005; 
Lipscombe et al., 2015 ). One study in Kentucky found that women with diabetes had a 
significantly 50% lower odds of having regular mammography screening as compared to those 
without DM (Fleming et al., 2011).   
These findings highlight the need for a better understanding of how diabetes reduces 
persistence with screening mammography among elderly women with diabetes who are at higher 
risk of developing BC.  These studies have not adjusted for diabetes severity and diabetes-related 
complications as a confounder; however, this factor may have a significant influence on this 
association.   
Few studies have examined the impact of diabetes-related complications on provision of 
preventive care (Conwell & Boult, 2008; Timar et al., 2016), but the influence of diabetes-related 
complications on having preventive services is only partly understood and focusing only on 
specific type of complications (Conwell & Boult, 2008;Timar et al., 2016).  
To date, no study has addressed the impact of diabetes severity and diabetes-related 
complications on persistence with screening mammography among women with diabetes. 
Therefore, the primary aim of this study is to examine the association between the severity of 
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diabetes complications and persistence with screening mammography among elderly women 
with diabetes by comparing them to women who have diabetes with no complications.  
Conceptual Framework  
The association between the severity of diabetes complications and persistence with 
screening mammography is the focus of this study. However, there are other covariates that 
could affect this association. Thus, we used the expanded Andersen behavioral model to guide 
the selection of other independent variables that may affect persistence with BC screening 
(Andersen, 1995). This model suggests that healthcare services utilization, such as breast cancer 
screening use depends upon predisposing factors, enabling factors, need factors, and the external 
environment factors (Figure 1).  Predisposing factors include individual factors such as 
demographic characteristics (e.g. age) biological imperative (e.g. sex), or social factors 
(ethnicity) (Andersen, 2001). Enabling factors are conditions enabling services utilization or 
factors entail whether an individual has a regular source of care. Need factors include assessment 
and measurement of patients’ health status and need for medical care (e.g. comorbid conditions).  
External environmental factors include metropolitan status and regions.   
RESEARCH DESIGN AND METHODS 
Study Design 
This study was a retrospective cohort study among elderly women with DM. The baseline 
years in which the individuals were first identified with DM were 2002-2008.  In each year, there 
was 12-months enrollment period, and then each case was followed up to 60 months to assess the 
impact of diabetes complications severity on persistence with screening mammography (Figure 
2).   
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Data Source 
We used a 5% random sample data of Surveillance Epidemiology and End Results 
(SEER)-non-cancer linked with Medicare files and generated in a file called the Summarized 
Denominator (SUMDENOM) file (SEER-Medicare, 2016). This database consists of Medicare 
beneficiaries who are free of cancer living in SEER areas (Atlanta, Connecticut, Detroit, Hawaii, 
Iowa, New Mexico, San Francisco-Oakland, Seattle-Puget Sound, Utah, Los Angeles and San 
Jose-Monterey, Rural Georgia, Alaska Native, Greater California, Kentucky, Louisiana, New 
Jersey, and Greater Georgia)( SEER, 2016; Hellman, 1997). The linked Medicare file provides 
claims of hospitalizations recorded for part A enrollees in Medicare Provider Analysis and 
Review (MEDPAR) file, and claims of care delivered in hospital outpatient departments and 
physician’s offices for part B enrollees in an outpatient (OUTPT) file and National Claims 
History (NCH) file. Also, Medicare files contain the Home Health Agency (HHA) file of all 
claims for home health services (SEER-Medicare, 2016).  
This database has been used to study factors and behaviors related to multiple types of 
cancer screening among Medicare population who are free of cancer (Kagay, Quale, & Smith-
Bindman, 2006; McBean & Yu, 2007; White, Vernon et al., 2011). Variables are created based 
on enrollment records in SUMDENOM file and medical claims using International Classification 
of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM) diagnosis and procedure codes, 
Current Procedural Terminology (CPT) codes, and Healthcare Common Procedure Coding 
System (HCPCS) codes.  
Study Cohorts 
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Our cohort consisted of elderly women aged 65 years or older with DM in the 5% 
random sample of non-cancer cases in the SEER-Medicare during the years 2002 to 2008. Other 
inclusion criteria were at least 6-years continuous enrollment in Medicare part A and B, no 
enrollment in a health maintenance organization (HMO) at any time during the study period, 
without any type of cancer, without end stage renal disease (ESRD), and alive during the study 
period. Diabetes was determined on the basis of either a single inpatient claim or at least two 
outpatient claim diagnoses with ICD-9-CM diagnosis code of 250.xx (Luo et al., 2014) during 
the 12-month period of continuous enrollment of the baseline period.   
Measures   
Outcome variable  
The key outcome variable was persistence with screening mammography during the 
follow-up five years. We identified the screening mammography using HCPCS codes (76085, 
76092, 77052, 77057, 77063, G0202, and G0203), and ICD-9-CM diagnosis code V7612 which 
are assigned for only screening mammography (McBean & Yu, 2007). For each year during the 
follow-up period, each woman who had ≥ 1 mammogram screening were considered to have a one 
screening mammogram during that year. Thereafter, the total number of annual screening 
mammograms was calculated for each case during the follow-up period (5 years) with a maxim 
number equals to 5 and minimum number equals to 0. Based on the number of annual screening 
mammograms a woman had during the follow-up five years, the study cohort was categorized into 
non-users (no screening mammograms), non-persistent users (with 1–2 screening mammograms), 
and persistent users (with three or more screening mammograms) (Vyas et al., 2014).  
Key independent variable 
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The main independent variable was diabetes complications severity that was identified 
before the first observed mammogram screening. For those who do not have any mammogram 
screening during the 60-months follow-up period, we picked a random year to capture the 
diabetes severity. Diabetes complications severity was measured by end-organ damage and 
diabetes-related complications using the diabetic comorbidity severity index (DCSI). The DCSI 
was first developed by Young and colleagues to include 7 categories of diabetes complications: 
cardiovascular disease, nephropathy, retinopathy, peripheral vascular disease, cerebrovascular, 
neuropathy, and metabolic complications (Young et al., 2008). Theses complications were 
identified using International Classification of Diseases, Ninth Edition, Clinical Modification 
(ICD-9-CM) diagnosis code to represent gradations of the diabetes complications severity 
(Young et al., 2008). The index for each complication was categorized into 2 or 3 levels (no 
abnormality = 0, some abnormality = 1, and severe abnormality = 2), based on the presence and 
severity of the complication, and then the indices of all complications were added together to get 
the DCSI which is a 13-point scale with a range of 0-13 (Chang et al., 2012a; Young et al., 
2008). The study cohort was divided into 6 subgroups consisting of DCSI=0 (no complications), 
DCSI =1, DCSI=2, DCSI=3, DCSI=4, and DCSI ≥ 5 indication increasing number of diabetes 
complications and/or severity.  
Covariates  
The covariates were selected based on the expanded Andersen behavioral model 
(Andersen, 1995). Predisposing factors were identified in the baseline year, and these factors 
include race and age. Race was categorized into white, African-American, and others. Age was 
categorized into 65–70, 71-74, 75-79, and 80 years or older. Number of annual visits to primary 
care providers (PCPs) during the study period (6years) including the baseline year were classified 
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as an enabling factor. These visits were identified from Medicare claims using physician claims in 
NCH files for the services representing routine office visits. Like previous research (Baldwin et 
al., 2002; Fisher et al., 2013; Yu, McBean, & Virnig, 2007), we defined PCPs as providers who 
had the following specialties: general practice, family medicine, primary care internal medicine, 
geriatric medicine, and obstetrics and gynecology. For each case, there must be at least one visit 
to PCPs during a year to be counted as one annual visit toward the whole number of annual visits 
to PCPs during the study period. Based the on the above definition, the variable was categorized 
into 3 groups: 0 to 3 visits, 4 to 5 visits, and 6 visits. Need factor was defined as the presence or 
absence of the following chronic conditions: arthritis, asthma, chronic obstructive pulmonary 
disease (COPD), dementia, hyperlipidemia, hypertension, thyroid syndrome, osteoporosis, 
anxiety, and depression. All the chronic conditions were identified in the year that preceded the 
first observed mammogram screening. For those who did not have any mammogram screening 
during the 60-months follow-up period, we picked a random year to capture the chronic conditions. 
External environment factors consisted of SEER regions (Northeast, South, North Central, and 
West), and metropolitan status (metro, urban, and rural) of the individuals.  
Statistical Analyses  
Descriptive statistics were reported using frequencies and percentages since all the 
variables were categorical. Chi-square tests were used to test for significant differences in 
characteristics among the three groups based on use of screening mammography: non-users, non-
persistent, and the persistent. Statistical significance was defined as a p-value ≤ 0.05. The adjusted 
associations between persistence with screening mammogram and diabetes complications severity 
were examined in a series of three multinomial logistic regressions models.  
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Model 1 included only the severity of diabetes complications measured by DCSI; model 2 
additionally included enabling factor (the number of annual visits to PCPs); and model 3 included 
predisposing factors (race and age), enabling factor (the number of annual visits to PCPs), need 
factors (comorbid conditions), and the external environment characteristics (SEER regions and 
metropolitan status). In all models, “non-users”, who had no screening mammography during the 
follow-up period, were used as the reference group for the outcome. The parameter estimates were 
transformed to odds ratios and their corresponding 95 % confidence intervals (CI). All analyses 
were conducted using statistical analysis systems software SAS 9.4 (SAS® version 9.4, SAS 
Institute Inc., Cary, NC, USA). 
RESULTS 
Cohort Characteristics 
Of 60,756 women who were identified with DM in our 5% non-cancer random sample of 
Medicare data, 16,526 were eligible for our study based on the study inclusion and exclusion 
criteria (Figure 3). Table 1 presents the characteristics of the study cohort. The majority of 
women were white (73.5%), living in metro areas (79.7%), and had at least one PCP visit per 
year during the study period (6 years). The most common comorbid conditions among women 
with DM in our study cohort were hypertension (84.6%), hyperlipidemia (65.8%), arthritis 
(36.6%), thyroid syndrome (29.9%), osteoporosis (17.1%), COPD (14.4%), dementia (11.6%), 
and asthma (11.5%). About 42.5% of the women with DM did not receive any mammography 
screening during the follow-up five years, 28.1% were non-persistent and only had one or two 
mammography screenings, and 29.5 % were persistent with 3 or more mammography screening 
during the follow-up period. About 42.5% of the women in our study had no diabetes 
complications and 12.7% had DCSI ≥ 5. The minimum DCSI was 0 while the maximum DCSI 
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was 11.  The most frequent diabetes-related complications were cardiovascular complications 
(48.9%), cerebrovascular complications (18.5%), neuropathy (17.6%), nephropathy (17.5%), 
peripheral vascular disease (12.6%), while metabolic complications (0.6%) and retinopathy 
(7.4%) were less frequent among elderly women with DM (non-tabulated).   
Group Differences by Persistence with BC Screening 
Table 2 shows the bivariate associations between persistence with screening 
mammogram and other characteristics of the study cohort. The variables that were significantly 
associated with persistence with screening mammogram include DCSI, age groups, race, number 
of annual visits to PCPs, SEER regions, and metropolitan status. The comorbid conditions that 
were significantly associated with persistence with BC were arthritis, asthma, COPD, dementia, 
hyperlipidemia, hypertension, thyroid syndrome, osteoporosis, and depression.  
Among those who did not have any BC screening during the 60 months, the percentage 
of women with a high severity of diabetes complications (DCSI ≥ 5) was higher (21.8%) as 
compared to non-persistent (9.5%) and persistent (2.8%) groups. Also, those who were non-users 
of BC screening were more likely to have older ages as compared to non-persistent and 
persistent groups. Women who did not have any screening mammogram during the follow-up 60 
months were less likely to have annual PCP visits during the study period (75.7%) as compared 
to persistent group (85.5%). Also, they were more likely to have arthritis, asthma, dementia, and 
COPD, and they were less likely to have hyperlipidemia and hypertension.  
Associations with Persistence with BC Screening 
Table 3 depicts the unadjusted and adjusted associations between persistence with 
screening mammography and the severity of diabetes complications. Generally, the severity of 
32 
 
diabetes complications was significantly associated with less likelihood of BC screening use 
(either persistent or non-persistent use). In the unadjusted association, women with DCSI =1, 
DCSI =2, DCSI =3, DCSI =4, and DCSI ≥5 were 14% (OR = 0.86; 95% CI = 0.76-0.97), 45% 
(OR = 0.55; 95% CI = 0.50-0.62), 66% (OR = 0.34; 95% CI = 0.29-0.40), 81% (OR = 19; 95% 
CI = 0.16-0.22), and 93% (OR = 0.07; 95% CI = 0.06-0.09) less likely to be persistent with 
screening mammogram as compared to those without diabetes complications. 
 This strong association remained significant in model 2 even after controlling for annual 
visits to PCPs during the 60 months. In model 3, after controlling for predisposing factors, 
enabling factors, need factors, health behaviors, and external environmental factors, women with 
DCSI =1, DCSI =2, DCSI =3, DCSI =4, and DCSI ≥5 were 23% (OR = 0.77; 95% CI = 0.68-
0.89), 46% (OR = 0.54; 95% CI = 0.48-0.61), 66% (OR = 0.34; 95% CI = 0.29-0.41), 79% (OR 
= 21; 95% CI = 0.17-0.25), and 92% (OR = 0.08; 95% CI = 0.07-0.10) less likely to be 
persistence with screening mammography, as compared to those without diabetes complications.  
DISCUSSION 
This cohort study is the first to examine the association between the severity of diabetes 
complications and persistence with BC screening in a large nationally representative sample of 
elderly women who are Medicare beneficiaries, living in SEER areas and were free of cancer. It 
makes an important contribution to the current literature, as it moves beyond identifying the 
general association between diabetes and lower BC screening towards exploring the impact of 
severity of diabetes complications and other covariates on having BC screening.   
Our study showed that 42.5% of elderly women with DM had no screening 
mammography during 60 months of follow-up period. This is higher than what was found in the 
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general population of elderly women since a previous study reported that 21% of elderly women 
are non-users with no screening mammography during a 24-month follow-up period (McCarthy 
et al., 2000). Another study by Vyas et al, reported that 27.9% of elderly women who are 
Medicare beneficiaries in SEER areas were non users with no screening mammography over the 
60-months follow-up period (Vyas et al., 2014). Overall, this is consistent with previous 
literature regarding the underuse of BC screening among elderly women with DM as compared 
to those without diabetes (Beckman et al., 2001; Chan et al., 2014; Fleming et al., 2011; 
Lipscombe et al., 2005; Martinez-Huedo et al., 2012; McBean & Yu, 2007). The findings 
highlight the need for better understanding of the role diabetes in lower rates of BC screening.  
Our findings revealed that the severity of diabetes complications is significantly 
associated with lower persistence with screening mammography after controlling for 
predisposing factors, enabling factors, need factors, health behaviors, and external environment 
factors. As the DCSI increases, the likelihood of being persistent with screening mammography 
decreases. Women with DCSI =1, DCSI =2, DCSI =3, DCSI =4, and DCSI ≥5 were 26%, 48%, 
67%, 80%, and 92% less likely to be persistence with screening mammogram, respectively, as 
compared to those without diabetes complications. This association of presence and severity of 
diabetes complications with low persistence with screening mammogram was confirmed even in 
the presence of more frequent PCP visits as compared to those without complications. This 
draws attention to the role of primary care providers to increase the awareness of elderly women 
and their caregivers about the importance of BC screening, especially since these women are at a 
high risk of developing breast cancer. Theories was proposed to explain why some patients, who 
have frequent visits to primary care physicians, do not get preventive services. Time constraints 
could be a factor that may explain why the primary care providers do not give preventive care a 
34 
 
priority during the visits, especially among elderly women with diabetes complications. A 
previous study by Yarnall et al, showed the ability of physicians to comply with preventive 
services recommendations are limited with time (Yarnall et al., 2003). In our study cohort, the 
presence and severity of diabetes complications may take precedence over BC screening during 
annual visits to PCPs. Another reason could be related to a shorter life expectancy of women 
with more sever diabetes complications. Guidelines including ACS, American College of 
Radiology (ACR) guidelines, and American Geriatrics Society (AGS) recommend that decisions 
about BC screening in elderly women should be considered based on the woman’s current health 
conditions and predicted life expectancy. Young et al found that as the DCSI increased, the 
mortality risk increased (Young et al., 2008). However, still having BC screening decreases the 
burden of comorbidity between the diabetes complications and cancer among elderly women 
with diabetes. Since elderly women with diabetes are at high risk of breast cancer diagnosis, new 
approaches and guidelines of preventive care are required to address the complexity and 
heterogeneity of diabetes, and to detect BC early, and thereby this could improve the chances 
that BC can be treated successfully (Braithwaite, Demb, & Henderson, 2016).    
The results of this study should be interpreted in the light of potential limitations of the 
methodology. Although the non-cancer SEER-Medicare sample of elderly women is a large 
linked data, it lacks the information related to mammogram screening covered by Medicare but 
not billed to Medicare. Second, since we used claims database instead of medical records to 
measure DSCI, the index was measured without laboratory results. However, a study by Chang 
et al. tested the validity of DCSI without laboratory results and they found that the DCSI without 
laboratory results and the DCSI with laboratory information perform similarly (Chang et al., 
2012b). Finally, the US Preventive Services Task Force (USPSTF) concluded that there is no 
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sufficient evidence to assess the importance of screening mammography in women aged 75 years 
or older because none of the randomized controlled trials evaluating screening mammography 
included women aged ≥ 74 years (Walter et al, 2014). However, we included elderly women 
aged ≥ 74 years in our cohort for many reasons. First, all other guidelines (ACS, ACOG, ACR, 
and AGS) do not recommend against having screening mammograms for women older than 74 
years. In addition, a study by Galit et al. revealed that regular mammography screening for 
women aged older than 74 years may be associated with lower risk of late stage diagnosis and 
lower mortality (Galit et al., 2007).  
Despite the potential limitations, this is the first cohort study, to investigate the contribution 
of the severity of diabetes complications using DCSI to low rates of screening mammograms 
among elderly women. In addition to use of DCSI as measure of diabetes severity, a study by 
Young et al. found that this index may be considered as a proxy measure for diabetes duration 
(Young et al., 2008). Young et al found that severity index of diabetes complications was highly 
correlated with diabetes duration, and it attenuated the significant impact of diabetes duration on 
mortality after it was added to the analysis model (Young et al., 2008).  Because diabetes may 
remained undiagnosed for years, using DCSI as a severity measure of long- term complications 
probably demonstrate the consequences of biologic markers of diabetes duration (Harris & 
Eastman, 2000).  Moreover, this is the only study that accounts for differences in comorbidities, 
access to health care, and other factors between non-users, non-persistent, and persistent 
mammography uses among elderly women with DM. Another major strength of this study is the 
large size of the studied cohort. Moreover, using a 5% random sample of Medicare beneficiaries 
who lived in SEER areas enable us to exclude women with histories of any cancer from the 
study. Also, women who had any diagnostic code of any type of cancer were excluded from our 
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cohort to increase the probability that the identified screening mammograms were indeed for 
screening.   
Overall, the DCSI may be best used for women with diabetes who are at high risk of poor 
BC preventive care by diabetes management programs, such as Medicare chronic care 
management (CCM) services that include interventions, monitoring and education. Also, these 
programs should be directed to primary health care physicians who could effectively promote to 
BC preventive care since the association between annual visits to PCPs and persistence with 
screening mammography was very strong.  
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Figure 1: conceptual framework (Anderson’s behavioral model) 
 
 
 
 
 
Figure 2: Study design (retrospective cohort study) 
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Figure 3: Study Sample Selection Flowchart 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Women with DM in 5% non-cancer random sample of 
Medicare data (2002-2008)                              
(N=60,756) 
Without any cancer indicator (2002-2008)                     
(N=51,282) 
Excluded (N=9,474) 
With any cancer indicator (2002-2008) 
Aged ≥ 65 years                                                          
(N=41,826) 
Excluded (N=9,456) 
Aged < 65 years 
With no ESRD indicator                                                        
(N=41,628) 
Excluded (N=198) 
Had  ESRD indicator 
Alive during the study period (72 months)                      
(N=24,797) 
Excluded (N=16,831) 
Died during the study period (72 months) 
Were continuously enrolled in part A and B during the study 
period (72 months)                                                              
(N=22,053) 
Excluded (N=2,744) 
Were not continuously enrolled in part A and B during 
the study period (72 months) 
Were not enrolled in HMO any time during the study period               
(72 months)                                                                      
(N=16,526) 
Excluded (N=5,527) 
Were enrolled in HMO any time during the study 
period (72 months) 
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Table 1: The Baseline Characteristics of the Study Cohort* by Diabetes Complications Severity Index (DSCI) 
Characteristics 
All 
(N) % 
DCSI=0 
(N) 
% DCSI=1 
(N) 
% DCSI=2 
(N) 
% DCSI=3 
(N) 
% DCSI=4 
(N) 
% DCSI=≥ 
5 (N) 
% 
TOTAL 16,526 100 6933  1882  2900  1277  1427  2107  
Age groups   
            
 65-70 5,896 35.7 2854 41.2 743 39.5 963 33.2 399 31.2 356 24.9 581 27.6 
 71-74 3,494 21.1 1562 22.5 407 21.6 599 20.7 252 19.7 274 19.2 400 19.0 
 75-79 3,684 22.3 1399 20.2 406 21.6 666 23.0 306 24.0 367 25.7 540 25.6 
 >=80 3,452 20.9 1118 16.1 326 17.3 672 23.2 320 25.1 430 30.1 586 27.8 
Race   
            
 White 12,147 73.5 5064 73.0 1395 74.1 2174 75.0 956 74.9 1056 74.0 1502 71.3 
 African America 2,355 14.3 955 13.8 237 12.6 392 13.5 180 14.1 203 14.2 388 18.4 
 Others 2,024 12.2 914 13.2 250 13.3 334 11.5 141 11.0 168 11.8 217 10.3 
Annual PCP visits    
            
 0-3 1,261 7.6 608 8.8 166 8.8 199 6.9 75 5.9 77 5.4 136 6.5 
 4-5 2,078 12.6 872 12.6 222 11.8 335 11.6 166 13.0 190 13.3 293 13.9 
 6 13,187 79.8 5453 78.7 1494 79.4 2366 81.6 1036 81.1 1160 81.3 1678 79.6 
Arthritis   
            
 Yes  6,056 36.6 1605 23.2 739 39.3 1140 39.3 643 50.4 684 47.9 1245 59.1 
 No 10,470 63.4 5328 76.8 1143 60.7 1760 60.7 634 49.6 743 52.1 862 40.9 
Asthma   
            
 Yes  1,896 11.5 442 6.4 204 10.8 393 13.6 197 15.4 223 15.6 437 20.7 
 No  14,630 88.5 6491 93.6 1678 89.2 2507 86.4 1080 84.6 1204 84.4 1670 79.3 
COPD   
             
 Yes  3,283 19.9 606 8.7 288 15.3 668 23.0 346 27.1 441 30.9 934 44.3 
 No  13,243 80.1 6327 91.3 1594 84.7 2232 77.0 931 72.9 986 69.1 1173 55.7 
Dementia   
            
 Yes  1,909 11.6 243 3.5 129 6.9 320 11.0 204 16.0 331 23.2 682 32.4 
 No  14,617 88.4 6690 96.5 1753 93.1 2580 89.0 1073 84.0 1096 76.8 1425 67.6 
Hyperlipidemia   
            
 Yes 10,869 65.8 3840 55.4 1311 69.7 2017 69.6 968 75.8 1055 73.9 1678 79.6 
 No  5,657 34.2 3093 44.6 571 30.3 883 30.4 309 24.2 372 26.1 429 20.4 
Hypertension   
            
 Yes  13,983 84.6 4974 71.7 1694 90.0 2655 91.6 1216 95.2 1370 96.0 2074 98.4 
 No  2,543 15.4 1959 28.3 188 10.0 245 8.4 61 4.8 57 4.0 33 1.6 
Thyroid syndrome   
            
 Yes  4,947 29.9 1546 22.3 551 29.3 953 32.9 478 37.4 517 36.2 902 42.8 
 No  11,579 70.1 5387 77.7 1331 70.7 1947 67.1 799 62.6 910 63.8 1205 57.2 
Osteoporosis   
            
 Yes  2,834 17.1 729 10.5 332 17.6 528 18.2 293 22.9 354 24.8 598 28.4 
 No  13,692 82.9 6204 89.5 1550 82.4 2372 81.8 984 77.1 1073 75.2 1509 71.6 
…Continued               
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Table 1: The Baseline Characteristics of the Study Cohort* by Diabetes Complications Severity Index (DSCI) 
Characteristics 
All 
(N) % 
DCSI=0 
(N) 
% DCSI=1 
(N) 
% DCSI=2 
(N) 
% DCSI=3 
(N) 
% DCSI=4 
(N) 
% DCSI=≥ 
5 (N) 
% 
Anxiety   
            
 Yes  633 3.8 167 2.4 77 4.1 118 4.1 60 4.7 77 5.4 134 6.4 
 No  15,893 96.2 6766 97.6 1805 95.9 2782 95.9 1217 95.3 1350 94.6 1973 93.6 
Depression   
            
 Yes 1,133 6.9 321 4.6 120 6.4 180 6.2 108 8.5 133 9.3 271 12.9 
 No 15,393 93.1 6612 95.4 1762 93.6 2720 93.8 1169 91.5 1294 90.7 1836 87.1 
SEER regions   
            
 Northeast 2,944 17.8 1197 17.3 332 17.6 559 19.3 237 18.6 272 19.1 347 16.5 
 South 4,205 25.4 1741 25.1 466 24.8 726 25.0 314 24.6 360 25.2 598 28.4 
 North-central 2,071 12.5 839 12.1 239 12.7 374 12.9 171 13.4 178 12.5 270 12.8 
 West 5,988 36.2 2663 38.4 707 37.6 997 34.4 449 35.2 494 34.6 678 32.2 
 Missing 1,318 8.0 493 7.1 138 7.3 244 8.4 106 8.3 123 8.6 214 10.2 
Metropolitan status   
            
 Metro 13,157 79.7 5530 79.8 1506 80.1 2331 80.5 1015 79.6 1165 81.8 1610 76.5 
 Urban 2,942 17.8 1222 17.6 335 17.8 500 17.3 231 18.1 224 15.7 430 20.4 
 Rural 409 2.5 175 2.5 38 2.0 66 2.3 29 2.3 36 2.5 65 3.1 
                
*A cohort of 16,526 elderly women with DM and free of cancer using SEER-Medicare dataset. 
DCSI = Diabetes complications severity index; PCP = Primary care providers;  
COPD = Chronic Obstructive Pulmonary Disorder; SEER = Surveillance, Epidemiology, and End Results; BC = Breast cancer.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
             
45 
 
Table 2: Characteristics of the Study Cohort* by Persistence with BC screening 
Characteristics Non-user Non-persistent Persistent  
 N % N % N % sig 
Total 7021  4637  4868   
DCSI        *** 
 DCSI = 0 2275 32.4 1831 39.5 2827 58.1  
 DCSI = 1 601 8.6 639 13.8 642 13.2  
 DCSI = 2 1195 17.0 883 19.0 822 16.9  
 DCSI = 3 598 8.5 427 9.2 252 5.2  
 DCSI = 4 822 11.7 415 8.9 190 3.9  
 DCSI >=5 1530 21.8 442 9.5 135 2.8  
Age groups       *** 
 65-70 1806 25.7 1824 39.3 2266 46.5  
 71-74 1276 18.2 1030 22.2 1188 24.4  
 75-79 1679 23.9 1049 22.6 956 19.6  
 >=80 2260 32.2 734 15.8 458 9.4  
Race        *** 
 White 5049 71.9 3348 72.2 3750 77.0  
 African America 984 14.0 702 15.1 669 13.7  
 others 988 14.1 587 12.7 449 9.2  
Number of annual PCP visits      *** 
 PCP=0-3 686 9.8 332 7.2 243 5.0  
 PCP=4-5 1017 14.5 599 12.9 462 9.5  
 PCP=6 5318 75.7 3706 79.9 4163 85.5  
Arthritis        *** 
 Yes  2922 41.6 1722 37.1 1412 29.0  
 No  4099 58.4 2915 62.9 3456 71.0  
Asthma        *** 
 Yes  860 12.2 592 12.8 444 9.1  
 No  6161 87.8 4045 87.2 4424 90.9  
COPD        *** 
 Yes  1774 25.3 945 20.4 564 11.6  
 No  5247 74.7 3692 79.6 4304 88.4  
Dementia       *** 
 Yes  1539 21.9 291 6.3 79 1.6  
 No  5482 78.1 4346 93.7 4789 98.4  
Hyperlipidemia       *** 
 Yes  4229 60.2 3262 70.3 3378 69.4  
 No  2792 39.8 1375 29.7 1490 30.6  
Hypertension       *** 
 Yes  5801 82.6 4131 89.1 4051 83.2  
 No  1220 17.4 506 10.9 817 16.8  
…Continued         
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Table 2: Characteristics of the Study Cohort* by Persistence with BC screening 
Characteristics Non-user Non-persistent Persistent  
 N % N % N % sig 
Thyroid syndrome       * 
 Yes  2134 30.4 1422 30.7 1391 28.6  
 No  4887 69.6 3215 69.3 3477 71.4  
Osteoporosis       *** 
 Yes  1369 19.5 762 16.4 703 14.4  
 No  5652 80.5 3875 83.6 4165 85.6  
Anxiety         
 Yes  279 4.0 184 4.0 170 3.5  
 No  6742 96.0 4453 96.0 4698 96.5  
Depression       *** 
 Yes  534 7.6 338 7.3 261 5.4  
 No  6487 92.4 4299 92.7 4607 94.6  
Anxiety         
 Yes  279 4.0 185 4.0 170 3.5  
 No  6742 96.0 4452 96.0 4698 96.5  
SEER regions       *** 
 Northeast 1355 19.3 780 16.8 809 16.6  
 South 1716 24.4 1179 25.4 1310 26.9  
 North-central 822 11.7 569 12.3 680 14.0  
 West 2507 35.7 1725 37.2 1756 36.1  
 Missing 621 8.8 384 8.3 313 6.4  
Metropolitan status       ** 
 Metro 5586 79.7 3627 78.3 3944 81.0  
 Urban 1227 17.5 890 19.2 825 17.0  
 Rural 193 2.8 118 2.5 98 2.0  
*A cohort of 16,526 elderly women with DM and free of cancer using SEER-Medicare dataset.                          
DCSI = Diabetes complications severity index; PCP = Primary care providers; COPD = Chronic Obstructive 
Pulmonary Disorder; SEER = Surveillance, Epidemiology, and End Results; BC = Breast cancer; Asterisks 
represent statistically significant group differences based on χ2 tests by 
persistence with mammography screening:  *** p<0.001; ** 0.001 < p <0.01; * 0.01 < p<0.05 
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Table 3: Association of Diabetes Complication Severity Index with Persistence with Breast 
Cancer Screening among Elderly women with Diabetes Mellitus 
 Variables Non-persistent Persistent 
 
 OR 95% CI sig OR 95% CI sig 
Model 1       
 DCSI categories       
  DCSI = 0 Ref   Ref   
 
 DCSI =1  1.32 [ 1.16, 1.50] *** 0.86 [ 0.76, 0.97] * 
 
 DCSI =2  0.92 [ 0.83, 1.02]  0.55 [ 0.50, 0.62] *** 
 
 DCSI =3   0.89 [ 0.77, 1.02]  0.34 [ 0.29, 0.40] *** 
 
 DCSI =4   0.63 [ 0.55, 0.71] *** 0.19 [ 0.16, 0.22] *** 
 
 DCSI ≥ 5 0.36 [ 0.32, 0.41] *** 0.07 [ 0.06, 0.09] *** 
Model 2       
 DCSI categories       
 
 DCSI = 0 Ref   Ref   
 
 DCSI = 1    1.32 [ 1.16, 1.50] *** 0.85 [ 0.75, 0.97] * 
 
 DCSI = 2   0.90 [ 0.81, 1.01]  0.54 [ 0.48, 0.60] *** 
 
 DCSI = 3  0.87 [ 0.76, 1.00]  0.33 [ 0.28, 0.38] *** 
  DCSI = 4   0.61 [ 0.53, 0.70] *** 0.18 [ 0.15, 0.21] *** 
  DCSI ≥ 5 0.35 [ 0.31, 0.40] *** 0.07 [ 0.06, 0.08] *** 
Model 3       
 DCSI categories       
 
 DCSI = 0 Ref   Ref   
 
 DCSI =1   1.13 [ 0.99, 1.30]  0.77 [ 0.68, 0.89] *** 
 
 DCSI =2   0.82 [ 0.73, 0.92] *** 0.54 [ 0.48, 0.61] *** 
 
 DCSI =3   0.78 [ 0.67, 0.91] ** 0.34 [ 0.29, 0.41] *** 
 
 DCSI =4   0.59 [ 0.51, 0.69] *** 0.21 [ 0.17, 0.25] *** 
 
 DCSI >=5  0.32 [ 0.28, 0.37] *** 0.08 [ 0.07, 0.10] *** 
         
DCSI = Diabetes complications severity index; BC = Breast cancer; OR = Odds ratio; CI = Confidence intervals.                                                                                                                                                                                                                                                                                                                                                                                                                                                   
Odds ratios and 95% CI from the multinomial regression models. 
Model 1 included only DCSI; Model 2 adjusted for enabling factor; and Model 3 adjusted for predisposing factors, 
enabling factor, need factors and external environmental factors.                                                                                                                                                                                                                   
Asterisks represent statistically significant group differences compared with the reference group:                              
*** p<0.001; ** 0.001 < p <0.01; * 0.01 < p<0.05  
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“Association between the Severity of Diabetes-related Complications and 
Stage of Breast Cancer at diagnosis among Elderly women with Pre-existing 
Diabetes Mellitus”  
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ABSTRACT 
Objective: To assess the association between the severity of diabetes complications and stage of 
breast cancer (BC) at diagnosis among elderly women with pre-existing diabetes mellitus.  
Methods: Using Surveillance, Epidemiology and End Results and Medicare linked data (2004–
2011), we identified women with incident BC and pre-existing diabetes (N = 7,729). Chi-square 
tests were used to test for group differences in stage of BC at diagnosis by the cohort 
characteristics that included mammography screening, biological factors (severity of diabetes 
complications using diabetes complications severity index (DCSI), age, race, hormone receptors 
(HR) status, and comorbid conditions), and non-biological factors such as access to health care 
and other community related factors. Multinomial logistic regression was used to examine the 
unadjusted and adjusted associations between the severity of diabetes complications and stage of 
BC at diagnosis.  
Results: Of women with incident BC and pre-existing diabetes in our study, 45.2% had 
cardiovascular complications, 19.5% had nephropathy, and 13.6% had neuropathy. Fifteen 
percent of the BC incident cases were diagnosed at stage 0, 38.4% at stage I, 29.1% at stage II, 
and 17.5% at advanced stages (III/IV). In univariate analyses, stage of BC at diagnosis was 
associated with severity of diabetes complications, mammography screening use, age, race, 
progesterone hormone receptor status, estrogen hormone receptor status, other comorbid 
conditions, having a visit to a primary care physician during the year before BC diagnosis, 
having a visit to an endocrinologist during the year before BC diagnosis, availability of BC 
screening centers, census tract education, and census tract household income. In partial adjusted 
association, severity of diabetes complications (DCSI=2 and DCSI ≥3) was associated with 
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higher likelihood of being diagnosed at advanced stages of BC after controlling for biological 
and non-biological factors. Women with DCSI ≥3 were 27% (odds ratio (OR) =1.27; 95% 
confidence interval (CI) = 1.05-1.54), 47% (OR = 1.47; 95 % CI = 1.20–1.80), and 62% (OR = 
1.62; 95 % CI = 1.30–2.01) more likely to be diagnosed at stage I, stage II, and advanced stages 
(III/IV), respectively, as compared to those with no diabetes complications. In full adjusted 
association, the severity of diabetes complications was no longer an independent predictor of BC 
stage II or advanced stage (III/IV) at diagnosis after controlling for biological factors, non-
biological factors, and BC screening. However, women with DCSI =2 had significantly 1.26 
times more likely to be diagnosed at stage I (versus stage 0) of BC, compared to those without 
diabetes complications (OR = 1.26; 95% CI = 1.03-1.53).  Women who had at least one 
screening mammogram during the last 24 months before BC diagnosis were 44%, 81%, and 91% 
less likely to be diagnosed at stage I, stage II, and advanced stages (III/IV), respectively, as 
compared to women who did not received screening.   
Conclusion: The increased likelihood of having advanced-stage BC at diagnosis associated with 
severity of diabetes-related complications appears to be mediated by lower rates of breast cancer 
screening among women with pre-existing diabetes. Therefore, reducing disparity in receiving 
breast cancer screening among women with diabetes may reduce the risk of advanced stage 
breast cancer diagnosis. 
Keywords:  Diabetes complications; breast cancer stage; mammography 
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INTRODUCTION  
Several previous studies have found that women with diabetes were more likely to be 
diagnosed in advanced stages of breast cancer (BC) as compared to those without diabetes, and 
this may contribute to their higher mortality after cancer diagnosis ( Lipscombe et al., 2015; Luo 
et al., 2015; van de Poll-Franse et al., 2007). A study conducted among Canadian women with 
incident BC showed that diabetes was associated with 21% increased risk of Stage III diagnosis 
and 16% increased risk of Stage IV diagnosis of BC as compared to women without diabetes 
(Lipscombe et al., 2015; Luo et al., 2015).  
Many reasons have been put forward to possibly account for later stage diagnosis of BC 
among women with diabetes. Studies have showed that women with diabetes are more likely to 
be diagnosed with metastatic BC and more likely to have larger tumors as compared to those 
without diabetes (Giovannucci et al., 2010). Lower rates of screening mammography among 
women with diabetes could also account for later stage diagnosis of BC. Despite the fact that 
women with diabetes have more frequent primary health care visits than women without 
diabetes, women with diabetes are less likely to have mammogram screening than women 
without diabetes (Lipscombe, Hux, & Booth, 2005). This lower rates of BC screening could play 
a role in the association between diabetes and risk of advanced stages of BC at diagnosis.  
Age and age-related changes also play a crucial role in the association between diabetes 
and advanced stage diagnosis of BC. About 40% of the newly diagnosed BC occur in elderly 
women (age ≥ 65 years) with a 3- to 4-fold higher mortality rate after BC diagnosis in 
comparison to their counterpart (Cappellani et al., 2013; Tesarova, 2013; Wildiers et al., 2007). 
Moreover, elderly women are more likely to be diagnosed at advanced stages of breast cancer 
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than younger women (Freyer et al., 2006; Khan, Stewart, & Morrow, 2002). Furthermore, one 
third of the elderly women population have pre-exiting diabetes (Corriere, Rooparinesingh, & 
Kalyani, 2013). Elderly women with diabetes have more frequent microvascular and 
macrovascular complications as compared to younger population (Corriere et al., 2013; Jin et al., 
2012).   
Since elderly women with DM have a higher likelihood of complications and advanced 
stage BC, it is important to determine how the severity of these complications contributes to 
advanced staged BC at diagnosis. 
Thus, the aim of this study is to determine the association between the severity of 
diabetes complications and stage of BC at diagnosis in women with incident BC and pre-existing 
diabetes.   
Conceptual Framework  
We used Danforth’s model to guide the selection of covariates that may affect the 
association between the severity of diabetes complications and BC stage (Figure1). This model 
suggests that the differences in BC stage at diagnosis is affected by biological factors, and non-
biological factors ( Danforth, 2013). The biological factors include age at diagnosis, race, hormone 
receptor (HR) status, and comorbidities. The non-biological factors include community-related 
factors ( Census tract level socioeconomic status (SES), region, and metropolitan status ) and 
access to health care (primary care visits, and availability of BC screening facilities in the area of 
residence) ( Danforth, 2013).   
RESEARCH DESIGN AND METHODS 
Study Design 
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This was a retrospective observational study in a cohort of elderly women with incident 
BC diagnosis and pre-existing diabetes. The cohort was followed retrospectively for 24 months 
prior to the BC diagnosis to assess the association between the severity of diabetes complications 
and stage of BC at diagnosis.  
Data Source 
We used the US Surveillance Epidemiology and End Results (SEER) data linked with 
Medicare claims data (SEER-Medicare). SEER is supported by the US National Cancer Institute 
(NCI) to collect data from tumor registries which covered 14% to 25% of the US population 
including all incident cases of cancer that occur in persons residing in 18 SEER areas (Atlanta, 
Connecticut, Detroit, Hawaii, Iowa, New Mexico, San Francisco-Oakland, Seattle-Puget Sound, 
Utah, Los Angeles and San Jose-Monterey, Rural Georgia, Alaska Native, Greater California, 
Kentucky, Louisiana, New Jersey, and Greater Georgia) (Hellman, 1997). Information of 
individuals in the SEER database who have been matched with Medicare enrollment records is in 
a customized file known as the Patient Entitlement and Diagnosis Summary File (PEDSF). This 
information includes demographic features, date of cancer diagnosis, cancer site, method of 
diagnosis, and state of residence. For Medicare claims files, it covers 97% of the US population 
who are 65 years or older (Potosky et al., 1993). The claims database consists of Medicare 
Provider Analysis and Review (MEDPAR), the Carrier Claims (old name Physician/Supplier 
(NCH)), Outpatient (OUTPT), Home Health Agencies (HHA), Hospice, Durable Medical 
Equipment (DME) and Part D Event (PDE) files. All of these Medicare data files have been 
linked with PEDSF file of cancer cases from SEER using an algorithm based on the social 
security number, last name, first name and date of birth of an individual. Based on the linkage, a 
common identification number is given to each enrollee in PEDSF and claims files. We also 
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linked the Area Resource File (ARF) to the SEER-Medicare dataset using the state and county 
Federal Information Processing Standards code for each beneficiary to extract the county level 
information on the availability of mammography facilities. 
Study Cohort 
Our cohort consisted of elderly women aged 67 years and older with the first primary 
diagnosis of incident BC between January 1, 2004 and December 31, 2011 who had pre-existing 
diabetes. Women must have at least 24 months of continuous enrollment in Medicare part A and 
B prior to the BC diagnosis and must have no enrollment in health maintenance organization 
(HMO) at any time during the study period. Diabetes was determined on the basis of either a 
single inpatient claim or at least two outpatient claim diagnoses with International Classification 
of Diseases, Ninth Edition, Clinical Modification (ICD-9-CM) diagnosis code of 250.xx (Luo et 
al., 2014) during the 12-month that preceded BC diagnosis. Women who were diagnosed with 
BC via death certificate or autopsy, or were with any previous cancer diagnosis, unknown or 
missing BC stage information were excluded from the study cohort (Figure 2). 
Measures    
Outcome variable  
The outcome was cancer staging based on the American Joint Committee on Cancer's 
staging system. Stage at diagnosis (0-IV) of the cancer/tumor was taken from PEDSF file. For the 
study purpose, we will group out cohorts into four categories: elderly women with stage 0, stage 
I, stage II, and advanced stage (III & IV) at BC diagnosis.   
Key independent variable 
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The key independent variable was the severity of diabetes-related complications which 
was identified during the 12 months that preceded the BC diagnosis. The severity of diabetes-
related complications was measured by end-organ damage of diabetes using the diabetes 
comorbidity severity index (DCSI). The DCSI was first developed by Young and colleagues to 
include 7 categories of diabetes complications: cardiovascular disease, nephropathy, retinopathy, 
peripheral vascular disease, cerebrovascular, neuropathy, and metabolic complications. Theses 
complications were identified using International Classification of Diseases, Ninth Edition, 
Clinical Modification (ICD-9-CM) diagnosis code to represent gradations of the diabetes 
complications severity (Young et al., 2008). The index for each complication was categorized 
into 2 or 3 levels (no abnormality = 0, some abnormality = 1, and severe abnormality = 2), based 
on the presence and severity of the complication, and the indices of all complications were added 
together to get the DCSI which is a 13-point scale with a range of 0-13 (Chang et al., 2012a; 
Young et al., 2008). The study cohort was divided into 4 subgroups consisting of DCSI=0, 
DCSI=1, DCSI=2, and DCSI ≥ 3. 
Other independent variables  
These variables were biological factors, non-biological factors, and mammography 
screening use.  
The biological factors included age at diagnosis, race, HR status, and other comorbid 
conditions. Age at BC diagnosis and race were decided using the SEER PEDSF file. Age at 
diagnosis was categorized as follows (in years): 67–70, 71–74, 75–79, and 80+. Race was 
categorized based into “White”, “African-American”, or “Other”. ICD-9 diagnosis codes in the 
Medicare inpatient and outpatient claims were used to identify the comorbid conditions. For HR 
status, SEER has recorded the estrogen receptor status and progesterone receptor status since 1990 
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for breast cancer cases. The hormone receptor status is categorized into positive, negative, and 
borderline/unknown (Elkin et al., 2006). The comorbid conditions were measured as the presence 
or absence of the following chronic conditions: thyroid syndrome, arthritis, asthma, Chronic 
Obstructive Pulmonary Disorder (COPD), dementia, hypertension, osteoporosis, anxiety, and 
depression.  
The non-biological factors include access to health care (PCP visits, endocrinologist 
visits, and availability of BC screening facilities around area of women’s residence) and 
community-related factors (census tract median household income, census tract-level education, 
geographic region of residence, and metropolitan status). We defined PCP as providers who had 
the following specialties: general practice, family medicine, primary care internal medicine, 
geriatric medicine, and obstetrics and gynecology. PCPs visits and endocrinologist visits were 
measured during the 12 months prior to BC diagnosis and was categorized into dichotomous 
group: yes (having at least one visit during the year that preceded BC diagnosis) or none. The 
availability of BC screening facilities in the area around women’s residence was derived from 
the ARF file and dichotomized into yes or no. Education percentage was measured by the census 
tract survey of percent of people age > 25 with at least 4 years of college education. Census tract 
education percentage was categorized into 0-13.29%, 13.30%-22.83%, 22.84%-38.55%, and 
>38.55%. Income was measured by census tract survey of median income and was divided into 
<$25,000, $25,001-50,000, $50,001-75,000, and >$75,000. Breast cancer screening was 
identified during the 24 months that preceded the BC diagnosis using Healthcare Common 
Procedure Coding System (HCPCS) codes: 76085, 76092, 77052, 77057, 77063, G0202, and 
G0203, and ICD-9-CM diagnosis code: V7612. Women must have had at least one 
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mammography screening during the past 24 months to be grouped into those who had BC 
screening.   
Statistical Analyses  
Descriptive statistics were obtained using frequencies and percentages for all included 
factors. Chi-square tests were used to test for significant differences among the four groups based 
on BC stage at diagnosis (0, I, II, and III/IV) among elderly women with diabetes in their baseline 
characteristics. The level of statistical significance was defined as a p-value ≤ 0.05. Only 
statistically significant covariates in bivariate analyses were used in multivariable multinomial 
logistic regression models. To examine the associations between stage of BC at diagnosis and the 
severity of diabetes-related complications using DCSI, we used three multinomial logistic 
regression models. The first model assessed the unadjusted association between stage of BC at 
diagnosis and the severity of diabetes-related complications. The second model was used to 
partially adjust for biological and non-biological factors (except mammography screening use). 
The third model was used to assess the full adjusted association between severity of diabetes 
complication and BC stage at diagnosis controlling for all covariates: biological factors, non-
biological factors and screening mammography use. The significance of the variables in the 
models was assessed by the Wald 2 test, odds ratios (ORs), and 95% confidence intervals (CIs).     
RESULTS 
Cohort Characteristics 
Table 1 describes the study cohort of 7,729 elderly women with pre-existing diabetes, 
aged 67 years and older, diagnosed with a first primary incident BC in 2004–2011.  About 15 % 
of the cohort were diagnosed at stage 0, 38.4% stage I, 29.1% stage II, and 17.7% were 
diagnosed at advanced stages (stage III or stage IV). About 57% of the study cohort had at least 
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one screening mammography during the last 24 months while 42.3% had no screening 
mammography. Twenty percent of the study cohort were ≤ 70 years old, 47.1% were in the age 
group 71–79 years, while 31.2% were ≥ 80 years old. A majority of the women were white (75.1 
%), had census tract income of $75,000 or less (81.6 %), resided in metro areas (79.3 %), had at 
least one PCP visit during the 12 months prior to the BC diagnosis (94.5 %), had no 
endocrinologist visits in the year that preceded BC diagnosis (88.1%), had positive progesterone 
HRS (71.2%), and had positive estrogen HRS (82.9%). For the most common comorbid chronic 
conditions, 70.4% had hyperlipidemia, 89.7% had hypertension, 28.3% had arthritis, and 15.8% 
had depression. With respect to DCSI, 38.4% had no diabetes-related complications, 13.1% had 
a DCSI =1, 23% had a DCSI =2, and 25.4% had a DCSI ≥ 3. Compared with women who had no 
diabetes complications, those with DCSI ≥ 3 were older, more likely to have had an 
endocrinologist visit, less likely to have had screening mammography, and more likely to have 
other comorbid conditions (arthritis, thyroid syndrome, COPD, dementia, hypertension, and 
depression). The most frequent diabetes-related complications were cardiovascular 
complications (45.2%), nephropathy (19.5%), neuropathy (13.6%), while metabolic 
complications (1%) and retinopathy (4.9%), cerebrovascular complications (8.9%), and 
peripheral vascular disease (9.7%) were less frequent among incident cases of BC with pre-
existing diabetes (non-tabulated).      
Group Differences by Stage of BC at Diagnosis 
Table 2 shows the group differences in all the independent variables by stage of BC at 
diagnosis. The biological factors that have significant bivariate associations with stage of BC at 
diagnosis were DCSI, age, race, progesterone HRS, estrogen HRS, thyroid disease, arthritis, 
COPD, dementia, hyperlipidemia, osteoporosis, and depression. The non-biological factors that 
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were statistically significant in the Chi-square analyses were mammography screening, PCP 
visits, endocrinologist visits, availability of BC screening centers, census tract education, and 
census tract household income. Regarding the main predictor, elderly women who were 
diagnosed with advanced stage (stage III/IV) BC were more likely to have a DCSI ≥ 3 (29.9%) 
as compared to those women who were diagnosed with stage 0 (21.7%). In contrast, elderly 
women who were diagnosed with stage 0 of BC were more likely to have no diabetes-related 
complications (43.9%) as compared to those who were diagnosed in advanced stage (III/IV) BC 
(34.5%). The proportions of women who had received screening mammography among elderly 
women with advanced stage (III/IV) BC (27.3%) and stage II BC (44.7%) were very low in 
comparison to women who were diagnosed in stage 0 (82.3%). For other biological factors, 
women with advanced stage (III/IV) BC diagnosis were less likely to have positive progesterone 
HRS, less likely to have thyroid disease, less likely to have hyperlipidemia, and more likely to 
have COPD, arthritis, and dementia as compared to women who were diagnosed with stage 0 of 
BC. For the non-biological factors, women with advanced stage BC diagnoses were less likely to 
have PCP visits, less likely to reside in areas with higher proportion of individuals with at least 4 
years of college education as compared to women who were diagnosed with stage 0 of BC.  
Associations with Stage of BC at Diagnosis     
The results from the multinomial logistic regressions are reported in table 3. Model 1 
presents the unadjusted association between the severity of diabetes complications using DCSI 
and stage of BC at diagnosis. In the unadjusted model, the severity of diabetes complications was 
significantly associated with BC stage at diagnosis. Women who had a DCSI =2 were 1.30 times 
more likely to be diagnosed at stages I (OR = 1.30; 95% CI = 1.08-1.56), 1.45 times more likely 
to be diagnosed at stage II (OR = 1.45; 95 % CI = 1.20–1.76), and 1.57 times more likely to be 
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diagnosed at advanced stage (III/IV) (OR = 1.57; 95 % CI = 1.27–1.93), as compared to those 
with no diabetes complications. Women who had the highest severity of diabetes-related 
complications (DCSI≥ 3) were 1.20 times more likely to be diagnosed at stage I (OR = 1.20; 
95% CI = 1.00-1.43), 1.50 times more likely to be diagnosed at stage II (OR = 1.50; 95 % CI = 
1.25–1.81), and 1.77 times more likely to be diagnosed at advanced stage (III/IV) (OR = 1.77; 95 
% CI = 1.45–2.17), as compared to those women with no diabetes complications.     
After assessing the partial adjusted association between severity of diabetes 
complications and stage of BC at diagnosis, controlling for biological and non-biological factors 
in model 2, we found that the severity of diabetes complication (a DCSI =2 and a DCSI ≥ 3) 
continue to be significantly associated with BC stage at diagnosis. For example, women with 
DCSI ≥3 were 27% more likely to be diagnosed at stage I, 47% more likely to be diagnosed at 
stage II, and 62% more likely to be diagnosed at advanced stages (III/IV) of BC.       
Model 3 shows the fully adjusted association between BC stage at diagnosis and severity 
of diabetes complications after controlling for biological factors, non-biological factors, and use 
of screening mammogram. Women with DCSI =2 were 26% more likely to be diagnosed at stage 
I (OR =1.26; 95% CI = 1.03-1.53) while there was no significant association with the likelihood 
of being diagnosed at stage II or advanced stages (III/IV) of BC, as compared to those with no 
diabetes complications. The highest severity of diabetes complications with DCSI ≥ 3 was no 
longer an independent predictor of BC stage at diagnosis. Women who had at least one screening 
mammogram during the two year that preceded BC diagnosis were 44% less likely to be 
diagnosed at stage I (OR = 0.56; 95% CI = 0.47-0.67), 81% less likely to be diagnosed at stage II 
(OR =0.19; 95% CI = 0.16-0.23), and 91% less likely to be diagnosed at advanced stages (III/IV) 
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(OR = 0.09; 95% CI = 0.08-0.11) of BC, as compared to women who did not receive any 
screening mammogram.       
DISCUSSION   
In this study, we examined the relationship between severity of diabetes-related 
complications and stage of BC at diagnosis among a large nationally representative sample of 
elderly women with pre-existing diabetes and an incident BC.    
Overall, severity of diabetes-related complications was associated with stage of BC at 
diagnosis. Adjustment for other biological and non-biological factors did not attenuate the 
association between severity of diabetes complications and BC stage at diagnosis. Our findings 
showed that among elderly women with pre-existing diabetes, women with a moderate severity 
of diabetes-related complications (a DCSI =2) were 32%, 42%, and 46% more likely to be 
diagnosed at stage I, stage II, and advanced stages (III/IV), respectively. Women with highest 
severity of diabetes-relates complications (DCSI ≥3) were 27%, 47%, and 62% more likely to be 
diagnosed at stage I, stage II, and advanced stages (III/IV), respectively, as compared to women 
with no diabetes complications. According to Lipscombe et al, presence of diabetes was 
associated with 11%  increased odds of stage II and advanced stages (III/IV) BC at diagnosis, as 
compared to women without diabetes ( Lipscombe et al., 2015).  
After adjustment for BC screening, women with a moderate severity of diabetes 
complications (a DCSI =2) were more likely to be diagnosed at stage I versus stage 0, as 
compared to women without diabetes complications. However, increased likelihood of being 
diagnosed at advanced stages of BC for elderly women with pre-existing diabetes did not reach 
statistical significance. Our results revealed that BC screening may mediate the association 
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between the severity of diabetes-related complications and likelihood of having advanced-stages 
BC at diagnosis. It is possible that increase in severity of diabetes complications result in 
decreases in screening mammography use which may lead to delayed diagnosis of BC. Thus, 
more advanced diabetes-related care is required to deal with the complexity of diabetes disease 
among elderly women to avoid the risk of serious comorbid condition, such as cancer in 
advanced stages which burden the disease management. One good example of such care is 
Medicare’s chronic care management that provide a comprehensive care coordination for elderly 
with multiple chronic conditions to facilitate access to care and receiving preventive care along 
with disease management (Garwood et al., 2016).  
Although previous research (Lipscombe et al., 2015; Luo et al., 2015) found that diabetes 
was an independent predictor of the risk of advanced stage (III/IV) BC at diagnosis as compared 
to women without diabetes even after accounting for BC screening mammography, we found 
that the severity of diabetes-related complications is associated with this risk through its negative 
impact on BC screening.  
The strengths of our study include modeling a comprehensive list of biological factors (e.g. 
comorbid conditions and hormone receptor status) and non-biological factors (e.g. access to 
health care, and community-related factors). To assess the severity of diabetes-related 
complications, we used DCSI which captures both the type and severity of complications while a 
simple count of complications does not take the severity of each complication into account 
(Young et al., 2008).  In addition to its use as a measure of diabetes severity, a study by Young et 
al. found that this index may be considered as a proxy measure for diabetes duration (Young et 
al., 2008). Young et al found that severity index of diabetes complications was highly correlated 
with diabetes duration, and it attenuated the significant impact of diabetes duration on mortality 
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after it was added to the analysis model (Young et al., 2008).  Because diabetes may remained 
undiagnosed for years, using DCSI as a severity measure of long- term complications probably 
demonstrate the consequences of biologic markers of diabetes duration (Harris & Eastman, 
2000).  Also, the use of large population-based data (SEER-Medicare) enabled us to identify 
incident breast cancer cases and assess all possible risk factors and pre-existing conditions.  
However, our study has several potential limitations that should be mentioned. Although we 
controlled for many biological and non-biological variables that could be associated with BC 
stage at diagnosis, we lacked data on other factors, such as obesity and family history of BC 
which could have residual confounding effect. Second, exclusions, such as 6 % of BC cases with 
missing stage of BC and 32% of BC cases with no continuous enrollment in part A & B or 
enrollment in HMO any time during the study period may have affected the generalizability of 
our findings. Third, since we used claims database instead of medical records to measure DSCI, 
the index was measured without laboratory results. However, a study by Chang et al. tested the 
validity of DCSI without laboratory results and they found that the DCSI without laboratory 
results and the DCSI with laboratory information perform similarly (Chang et al., 2012b). Other 
limitations include lack of some biological information, such as blood glucose level, and 
glycosylated hemoglobin A1c lab results. 
In conclusion, our study provides evidence that the severity of diabetes-related complications 
is associated with stage of BC at diagnosis and has an indirect association with the risk of 
advanced-stages diagnosis of BC among women with pre-existing diabetes. The increased 
likelihood of advanced-stage BC diagnosis that is associated with the severity of diabetes-related 
complications may be mainly driven by lower rates of BC screening among those with diabetes 
complications.  
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            Figure 1: Conceptual framework based on Danforth’s model 
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Figure 2: Study Cohort Selection Flowchart 
 
 
 
 
 
  
Women who diagnosed with breast cancer in SEER from 
January 01, 2004 to December 31, 2011                        
(N= 392,684) 
Diagnosed with Primary breast cancer                             
(N= 221,800) 
Excluded (N=170,884)                                          
Breast cancer was diagnosed as a secondary cancer or 
there are other types of cancer    
Incident cases of primary breast cancer                         
(N= 220,753) 
Excluded (N=1,047)                                               
Breast cancer was not an incident case 
Breast cancer was not diagnosed at autopsy or death             
(N= 219,263) 
Excluded (N=1,490)                                                 
Breast cancer was diagnosed at autopsy or death 
Aged ≥ 67                                                                                  
(N= 123,085) 
Excluded (N=96,178)                                                
Aged < 67 
Known stage of breast cancer at diagnosis                                 
(N= 115,554) 
Excluded (N=7,531)                                               
Missing or unknown stage of breast cancer at 
diagnosis 
Continuous enrollment in part A & B and no HMO enrollment at 
least 24 months before breast cancer diagnosis                           
(N= 78,269) 
Excluded (N=37,285)                                                   
No continuous enrollment in part A & B and no HMO 
enrollment at least 24 months before breast cancer 
diagnosis   
Excluded (N=70,540)                                                
Were not diagnosed with DM at least 12 months 
before breast cancer diagnosis 
Diagnosed with DM before breast cancer diagnosis                                                                                       
(N= 7,729) 
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Table 1: The Baseline Characteristics of the Study Cohort* by Diabetes Complications Severity Index  
 
All Women, 
N=7729 
DCSI=0, 
N= 2968 
DCSI=1, 
N= 1009 
DCSI=2, 
N= 1788 
DCSI≥3, 
N= 1964 
Characteristic  No. % No. % No. % No. % No. % 
Mammography screening  
        
 Annual/biennial 4463 57.7 1951 65.7 654 64.8 941 52.6 917 46.7 
 No screening  3266 42.3 1017 34.3 355 35.2 847 47.4 1047 53.3 
Age group   
        
 67-70 1677 21.7 774 26.1 239 23.7 301 16.8 363 18.5 
 71-74 2075 26.8 858 28.9 278 27.6 477 26.7 462 23.5 
 75-79 1566 20.3 572 19.3 201 19.9 371 20.7 422 21.5 
 >=80 2411 31.2 764 25.7 291 28.8 639 35.7 717 36.5 
Race   
        
 White 5804 75.1 2271 76.5 758 75.1 1373 76.8 1402 71.4 
 African American 1370 17.7 443 14.9 175 17.3 303 16.9 449 22.9 
 Others 555 7.2 254 8.6 76 7.5 112 6.3 113 5.8 
Progesterone receptor status  
        
 Positive 4840 62.6 1888 63.6 658 65.2 1119 62.6 1175 59.8 
 Negative 1957 25.3 756 25.5 244 24.2 435 24.3 522 26.6 
 Borderline/Unknown 932 12.1 324 10.9 107 10.6 234 13.1 267 13.6 
Estrogen receptor status    
        
 Positive 5718 74.0 2243 75.6 759 75.2 1313 73.4 1403 71.4 
 Negative 1177 15.2 447 15.1 155 15.4 262 14.7 313 15.9 
 Borderline/Unknown 834 10.8 278 9.4 95 9.4 213 11.9 248 12.6 
Thyroid syndrome   
        
 Yes  1862 24.1 592 19.9 264 26.2 459 25.7 547 27.9 
 No  5867 75.9 2376 80.1 745 73.8 1329 74.3 1417 72.1 
Arthritis   
        
 Yes 2188 28.3 736 24.8 313 31.0 518 29.0 621 31.6 
 No  5541 71.7 2232 75.2 696 69.0 1270 71.0 1343 68.4 
Asthma   
        
 Yes 624 8.1 170 5.7 73 7.2 195 10.9 186 9.5 
 No  7105 91.9 2798 94.3 936 92.8 1593 89.1 1778 90.5 
COPD   
        
 Yes 1222 15.8 239 8.1 118 11.7 380 21.3 485 24.7 
 No  6507 84.2 2729 91.9 891 88.3 1408 78.7 1479 75.3 
Dementia   
        
 Yes  625 8.1 148 5.0 66 6.5 162 9.1 249 12.7 
 No  7104 91.9 2820 95.0 943 93.5 1626 90.9 1715 87.3 
Hyperlipidemia   
        
 Yes  5443 70.4 2046 68.9 754 74.7 1242 69.5 1401 71.3 
 No  2286 29.6 922 31.1 255 25.3 546 30.5 563 28.7 
…Continued            
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Table 1: The Baseline Characteristics of the Study Cohort* by Diabetes Complications Severity Index  
 
All Women, 
N=7729 
DCSI=0, 
N= 2968 
DCSI=1, 
N= 1009 
DCSI=2, 
N= 1788 
DCSI≥3, 
N= 1964 
Characteristic  No. % No. % No. % No. % No. % 
Hypertension   
        
 Yes  6936 89.7 2489 83.9 919 91.1 1648 92.2 1880 95.7 
 No  793 10.3 479 16.1 90 8.9 140 7.8 84 4.3 
Osteoporosis   
        
 Yes  626 8.1 219 7.4 79 7.8 172 9.6 156 7.9 
 No  7103 91.9 2749 92.6 930 92.2 1616 90.4 1808 92.1 
Anxiety   
        
 Yes  767 9.9 217 7.3 115 11.4 200 11.2 235 12.0 
 No  6962 90.1 2751 92.7 894 88.6 1588 88.8 1729 88.0 
Depression   
        
 Yes 1221 15.8 340 11.5 172 17.0 311 17.4 398 20.3 
 No  6508 84.2 2628 88.5 837 83.0 1477 82.6 1566 79.7 
PCP visit   
        
 Yes 7301 94.5 2743 92.4 958 94.9 1714 95.9 1886 96.0 
 No 428 5.5 225 7.6 51 5.1 74 4.1 78 4.0 
Endocrinologist visit   
        
 Yes 919 11.9 252 8.5 143 14.2 198 11.1 326 16.6 
 No 6810 88.1 2716 91.5 866 85.8 1590 88.9 1638 83.4 
Availability of BC screening centers         
 Yes 3661 47.4 1408 47.4 470 46.6 856 47.9 927 47.2 
 No 4068 52.6 1560 52.6 539 53.4 932 52.1 1037 52.8 
Census tract education percentage  
        
 0-13.29% 1614 20.9 589 19.8 206 20.4 387 21.6 432 22.0 
 13.30%-22.83% 1773 22.9 703 23.7 215 21.3 387 21.6 468 23.8 
 22.84%-38.55% 1499 19.4 587 19.8 205 20.3 343 19.2 364 18.5 
 >38.55% 1251 16.2 502 16.9 168 16.7 298 16.7 283 14.4 
 Missing 1592 20.6 587 19.8 215 21.3 373 20.9 417 21.2 
Census tract household median income         
 < $25,000 488 6.4 178 6.0 62 6.2 106 6.0 142 7.3 
 $25,001-50,000 3327 43.3 1245 42.2 446 44.7 751 42.2 885 45.4 
 $50,001-75,000 2447 31.9 974 33.0 314 31.5 555 31.2 604 31.0 
 >$75,000 1413 18.4 553 18.7 175 17.6 366 20.6 319 16.4 
SEER region   
        
 Northeast 1336 17.3 494 16.6 174 17.2 344 19.2 324 16.5 
 South 2346 30.4 835 28.1 288 28.5 561 31.4 662 33.7 
 North-central 1332 17.2 527 17.8 188 18.6 283 15.8 334 17.0 
 West 2715 35.1 1112 37.5 359 35.6 600 33.6 644 32.8 
            
…Continued           
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Table 1: The Baseline Characteristics of the Study Cohort* by Diabetes Complications Severity Index  
 
All Women, 
N=7729 
DCSI=0, 
N= 2968 
DCSI=1, 
N= 1009 
DCSI=2, 
N= 1788 
DCSI≥3, 
N= 1964 
Characteristic  No. % No. % No. % No. % No. % 
Metropolitan status   
        
 Metro 6131 79.3 2315 78.0 821 81.4 1420 79.4 1575 80.2 
 Urban 1391 18.0 573 19.3 161 16.0 324 18.1 333 17.0 
 Rural 205 2.7 79 2.7 27 2.7 44 2.5 55 2.8 
       
        
*A cohort of 7,729 elderly women with incident breast cancer and pre-existing DM using SEER-Medicare dataset 
2004-2011. 
DCSI = Diabetes complications severity index; PCP = Primary care providers;  
COPD = Chronic Obstructive Pulmonary Disorder; SEER = Surveillance, Epidemiology, and End Results; BC = 
Breast cancer. 
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Table 2: Description of Elderly Women with Incident Breast Cancer and Pre-existing Diabetes mellitus by 
Stage at Diagnosis, SEER-Medicare 2004–2011 cases 
   
Stage 0 Stage I Stage II Stage III/IV 
 
Variables N % N % N % N % sig 
Total 1161 100 2968 100 2246 100 1354 100  
DCSI 
         
*** 
 
DCSI = 0 510 43.9 1173 39.5 818 36.4 467 34.5 
 
 
DCSI = 1 168 14.5 413 13.9 274 12.2 154 11.4 
 
 
DCSI = 2 231 19.9 688 23.2 541 24.1 328 24.2 
 
 
DCSI ≥ 3 252 21.7 694 23.4 613 27.3 405 29.9 
 
Mammography screening 
       
*** 
 
Annual/biennial 956 82.3 2133 71.9 1005 44.7 369 27.3 
 
 
No screening  205 17.7 835 28.1 1241 55.3 985 72.7 
 
Age group 
        
*** 
 
67-70 317 27.3 666 22.4 448 19.9 246 18.2 
 
 
71-74 367 31.6 803 27.1 565 25.2 340 25.1 
 
 
75-79 213 18.3 629 21.2 457 20.3 267 19.7 
 
 
>=80 264 22.7 870 29.3 776 34.6 501 37.0 
 
Race 
         
*** 
 
White 809 69.7 2339 78.8 1683 74.9 973 71.9 
 
 
African American 265 22.8 423 14.3 400 17.8 282 20.8 
 
 
Others 87 7.5 206 6.9 163 7.3 99 7.3 
 
Progesterone receptor status 
       
*** 
 
Positive 586 50.5 2121 71.5 1440 64.1 693 51.2 
 
 
Negative 221 19.0 635 21.4 647 28.8 454 33.5 
 
 Borderline/Unknown 354 30.5 212 7.1 159 7.1 207 15.3  
Estrogen receptor status   
       
*** 
 
Positive 707 60.9 2453 82.6 1704 75.9 854 63.1 
 
 
Negative 142 12.2 329 11.1 401 17.9 305 22.5 
 
 Borderline/Unknown 312 26.9 186 6.3 141 6.3 195 14.4  
Thyroid 
        
*** 
 
Yes  281 24.2 768 25.9 548 24.4 265 19.6 
 
 
No 880 75.8 2200 74.1 1698 75.6 1089 80.4 
 
Arthritis 
         
* 
 
Yes  287 24.7 854 28.8 645 28.7 402 29.7 
 
 
No  874 75.3 2114 71.2 1601 71.3 952 70.3 
 
Asthma 
          
 
Yes  93 8.0 257 8.7 187 8.3 87 6.4 
 
 
No 1068 92.0 2711 91.3 2059 91.7 1267 93.6 
 
           
           
…Continued          
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Table 2: Description of Elderly Women with Incident Breast Cancer and Pre-existing Diabetes mellitus by 
Stage at Diagnosis, SEER-Medicare 2004–2011 cases 
   
Stage 0 Stage I Stage II Stage III/IV 
 
Variables N % N % N % N % sig 
COPD 
         
*** 
 
Yes  150 12.9 440 14.8 365 16.3 267 19.7 
 
 
No  1011 87.1 2528 85.2 1881 83.7 1087 80.3 
 
Dementia 
        
*** 
 
Yes  56 4.8 150 5.1 233 10.4 186 13.7 
 
 
No  1105 95.2 2818 94.9 2013 89.6 1168 86.3 
 
Hyperlipidemia 
        
*** 
 
Yes  890 76.7 2214 74.6 1507 67.1 832 61.4 
 
 
No  271 23.3 754 25.4 739 32.9 522 38.6 
 
Hypertension 
         
 
Yes  1044 89.9 2671 90.0 2022 90.0 1199 88.6 
 
 
No 117 10.1 297 10.0 224 10.0 155 11.4 
 
Osteoporosis  
        
* 
 
Yes  99 8.5 266 9.0 152 6.8 109 8.1 
 
 
No  1062 91.5 2702 91.0 2094 93.2 1245 91.9 
 
Anxiety 
         
 
Yes  104 9.0 288 9.7 242 10.8 133 9.8 
 
 
No  1057 91.0 2680 90.3 2004 89.2 1221 90.2 
 
Depression 
        
*** 
 
Yes  160 13.8 427 14.4 399 17.8 235 17.4 
 
 
No  1001 86.2 2541 85.6 1847 82.2 1119 82.6 
 
PCP visit 
        
* 
 
Yes 1109 95.5 2820 95.0 2110 93.9 1262 93.2 
 
 
No 52 4.5 148 5.0 136 6.1 92 6.8 
 
Endocrinologist visit 
        
* 
 
Yes 162 14.0 370 12.5 243 10.8 144 10.6 
 
 
No 999 86.0 2598 87.5 2003 89.2 1210 89.4 
 
Availability of BC screening centers 
       
*** 
 
Yes 536 46.2 1490 50.2 1034 46.0 601 44.4 
 
 
No 625 53.8 1478 49.8 1212 54.0 753 55.6 
 
Census tract education 
        
** 
 
0-13.29% 236 20.3 573 19.3 494 22.0 311 236 
 
 
13.30%-22.83% 262 22.6 705 23.8 495 22.0 311 262 
 
 
22.84%-38.55% 230 19.8 612 20.6 410 18.3 247 230 
 
 
>38.55% 208 17.9 494 16.6 364 16.2 185 208 
 
 Missing 225 19.4 584 19.7 483 21.5 300 225  
           
...Continued          
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Table 2: Description of Elderly Women with Incident Breast Cancer and Pre-existing Diabetes mellitus by 
Stage at Diagnosis, SEER-Medicare 2004–2011 cases 
   
Stage 0 Stage I Stage II Stage III/IV 
 
Variables N % N % N % N % sig 
Census tract household income 
       
* 
 
< $25,000 72 6.3 174 5.9 142 6.4 100 7.5 
 
 
$25,001-50,000 490 42.5 1245 42.2 977 43.7 615 45.9 
 
 
$50,001-75,000 360 31.3 953 32.3 716 32.0 418 31.2 
 
 
>$75,000 230 20.0 576 19.5 400 17.9 207 15.4 
 
SEER region 
         
 
Northeast 194 16.7 492 16.6 393 17.5 257 19.0 
 
 
South 338 29.1 897 30.2 679 30.2 432 31.9 
 
 
North-central 225 19.4 503 16.9 374 16.7 230 17.0 
 
 
West 404 34.8 1076 36.3 800 35.6 435 32.1 
 
Metropolitan status 
         
 
Metro 940 81.0 2321 78.2 1782 79.3 1088 80.4 
 
 
Urban 195 16.8 562 18.9 400 17.8 234 17.3 
 
 
Rural 26 2.2 84 2.8 64 2.8 31 2.3 
 
           
DCSI = Diabetes complications severity index; PCP = Primary care providers; COPD = Chronic Obstructive 
Pulmonary Disorder; SEER = Surveillance, Epidemiology, and End Results; BC = Breast cancer; DM = Diabetes 
mellitus.                          
Asterisks represent statistically significant group differences based on χ2 tests by stage of BC at diagnosis:    
*** p<0.001; ** 0.001 < p <0.01; * 0.01 < p<0.05 
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Table 3: Association of Diabetes Complication Severity Index with Breast Cancer Stage at Diagnosis among 
Elderly women with pre-existing Diabetes mellitus 
    
Stage I Stage II Stage III/IV 
 
Variables OR 95% CI Sig OR 95% CI Sig OR 95% CI Sig 
Model 1 
         
 
DCSI 
         
  
DCSI = 0 Ref 
        
  
DCSI = 1 1.06 [ 0.86, 1.30]  1.01 [ 0.81, 1.26]  0.99 [ 0.77, 1.28]    
DCSI = 2 1.30 [ 1.08, 1.56] ** 1.45 [ 1.20, 1.76] *** 1.57 [ 1.27, 1.93] ***   
DCSI ≥ 3 1.20 [ 1.00, 1.43] * 1.50 [ 1.25, 1.81] *** 1.77 [ 1.45, 2.17] *** 
Model 2 
         
 
DCSI 
         
  
DCSI = 0 Ref 
        
  
DCSI = 1 1.05 [ 0.84, 1.31]  0.99 [ 0.79, 1.25]  1.00 [ 0.77, 1.30]    
DCSI = 2 1.32 [ 1.09, 1.61] ** 1.42 [ 1.16, 1.74] *** 1.46 [ 1.17, 1.83] ***   
DCSI ≥ 3 1.27 [ 1.05, 1.54] * 1.47 [ 1.20, 1.80] *** 1.62 [ 1.30, 2.01] *** 
Model 3 
         
 
DCSI 
         
  
DCSI = 0 Ref 
        
  
DCSI = 1 1.05 [ 0.84, 1.31]  0.98 [ 0.77, 1.25]  0.97 [ 0.74, 1.29]    
DCSI = 2 1.26 [ 1.03, 1.53] * 1.22 [ 0.99, 1.51]  1.17 [ 0.93, 1.48]    
DCSI ≥ 3 1.18 [ 0.97, 1.44]  1.17 [ 0.95, 1.44]  1.16 [ 0.92, 1.46]   
Mammography screening 
    
  
Annual/biennial 0.56 [ 0.47, 0.67] *** 0.19 [ 0.16, 0.23] *** 0.09 [ 0.08, 0.11] ***   
No screening  Ref 
        
            
DCSI = Diabetes complications severity index; BC = Breast cancer; OR = Odds ratio; AOR, adjusted odds ratio; CI 
= Confidence intervals.                                                                                                                                             
Model 1 contains DCSI only. Model 2 contains DCSI plus age, race. progesterone receptor status, estrogen receptor 
status, comorbid conditions (thyroid, arthritis, COPD, dementia, hyperlipidemia, osteoporosis, and depression), PCP 
visit, endocrinologist visit, availability of mammography screening centers, census tract education, and census tract 
household income. Model 3 contains Model 2 plus mammography screening.                                                                                                                                                                                                                          
Odds ratios and 95% CI from the multinomial logistic regression models                                                                                  
Asterisks represent statistically significant group differences compared with the reference group: 
***p<.001; **.001 < p <.01; * .01 < p<.05 
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CHAPTER FOUR 
 
 
 
“The Severity of Diabetes Complications in Relation to All-cause Mortality in 
Elderly Women with pre-exiting Diabetes and Incident Breast Cancer” 
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ABSTRACT 
Objective:  Since pre-existing diabetes has been associated with increased risk of all-cause 
mortality in incident breast cancer (BC) cases, it is prudent to investigate how diabetes-related 
complications and diabetes severity contribute to its impact on all-cause mortality of newly 
diagnosed BC cases. Therefore, the aim of this study was to explore the relationship between 
severity of diabetes complications and all-cause mortality in elderly women diagnosed with BC 
and pre-existing diabetes. 
Methods: Using the linked SEER-Medicare data, we included a cohort of women age ≥ 67 years 
diagnosed with BC from 2007 to 2011 and having pre-existing diabetes (N = 4,307) among 
Medicare beneficiaries who were continuously enrolled in Parts A and B 24 months before BC 
diagnosis and 6 months after BC diagnosis, and were continuously enrolled in Part D three 
months after BC diagnosis. Chi-square tests were used to test for significant difference in 3-years 
all-cause mortality based on severity of diabetes complications and other independent variables. 
Unadjusted and adjusted Cox proportional hazards models were used to estimate hazards ratios 
(HR) of all-cause mortality within 3 years of BC diagnosis based on severity of diabetes-related 
complications controlling for antidiabetic medication, cancer characteristics, patients-related 
factors and cancer treatment. 
Results: Adjusting for all available covariates among elderly women with pre-existing diabetes 
and incident BC, severity of diabetes complication was significantly associated with all-cause 
mortality within three years of BC diagnosis. Women with a DCSI =1, DCSI =2, and DCSI ≥3 
had 34% (HR = 1.34; 95% CI = 1.02-1.75), 69% (HR = 1.69; 95% CI = 1.39-2.05), and 124% 
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(HR = 2.24; 95% CI = 1.86-2.70) increased risk of death within 3 years after BC diagnosis, 
respectively, as compared to those without diabetes complications. 
Conclusions: Our findings suggest that severity of diabetes-related complications increase the 
risk of all-cause mortality of incidence breast cancer in elderly women with pre-existing 
diabetes. The continuum of diabetes care to control its complications after BC diagnosis along 
with cancer care is necessary to reduce mortality rates in incident BC cases with pre-existing 
diabetes.    
Keywords: All-cause mortality, Breast cancer, Diabetes, Diabetes Complications Severity Index  
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INTRODUCTION 
Elderly women with diabetes are burdened with aging process, disease complexity, 
comorbid conditions, and diabetes-related complications that are negatively impact their health 
outcomes (Laiteerapong, Huang, & Chin, 2011). Past studies have shown that diabetes-related 
complications are the major cause of deaths among individuals with diabetes (Cusick et al., 
2005).  A study by Cusick et al showed that the risk of mortality increases as the degree of 
diabetes complications worsens (Cusick et al., 2005) 
Also, elderly women with diabetes are at elevated risk of incident breast cancer (BC) 
through its direct pathophysiological effects and by its negative impact on BC screening use 
(Bernard et al., 2016; Onitilo et al., 2014). Approximately 16% of elderly women with BC 
have pre-existing diabetes (Wolf et al.,  2005). Diabetes is also associated with high mortality 
rate after BC diagnosis among women with diabetes as compared to women without diabetes 
(Barone et al., 2008; Cleveland et al., 2012; De Bruijn et al., 2013; Lam et al., 2011). Both age 
and diabetes are associated with decreased overall survival in elderly with incident breast 
cancer (Patnaik et al., 2011). A meta-analyses by Peairs et al demonstrated that diabetes was 
associated with a 49 % increase in risk of all-cause mortality among women with BC (Peairs et 
al., 2011). 
Although the severity of diabetes complications could contribute to higher mortality 
among women with diabetes, little is known about the impact of severity of diabetes-related 
complications on risk of all-cause mortality among incident BC cases. Evidence from previous 
literature has revealed that the presence of some diabetes complications could affect cancer 
therapy (Morsy & Heeba, 2016; Peairs et al., 2011; Volkova & Russell, 2011), which could 
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impact patients’ health outcomes. However, there are limited evidence in the literature on the 
direct impact of overall severity of diabetes-related complications on all-cause mortality of 
incident BC after controlling for cancer therapy and other possible risk factors.     
 Therefore, the objective of this study was to evaluate the relationship between severity 
of diabetes complications and all-cause mortality among elderly women with incident BC and 
pre-existing diabetes.  
Conceptual framework  
We used the model of comorbidity and cancer (Geraci et al., 2005) to guide our study. 
This model is useful to assess the potential impact of pre-existing specific comorbidity on cancer 
prognosis (e.g. survival and mortality) based on multivariable analyses (Geraci et al., 2005). This 
model has been widely used and validated among patients with breast, ovarian, and pancreatic 
cancers (Du et al., 2002; Hershman et al., 2004; Krzyzanowska, Weeks, & Earle, 2003).The 
model assumes that the overall likelihood of survival of patients with cancer decreases as the 
burden of comorbid conditions  increases (Piccirillo et al., 2004). Based on this model, all-cause 
mortality of incident BC was predicted by burden of pre-existing diabetes, which was measured 
by diabetes complications severity index (DCSI) controlling for the characteristics of incident 
BC, patient factors, and cancer treatment.  
RESEARCH DESIGN AND METHODS 
Study Design & Data Source 
This was a retrospective cohort study in elderly women with incident BC diagnosis and 
pre-existing diabetes using the linked SEER-Medicare dataset.  
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The SEER program is supported by the National Cancer Institute (NCI) to collect data 
from cancer registries including all incident cases of cancer that occur in SEER areas (Hellman, 
1997).  For each incident cancer identified, the SEER program collects information in a 
customized file known as the Patient Entitlement and Diagnosis Summary File (PEDSF) which 
contains demographic features, date of cancer diagnosis, cancer site, method of diagnosis, and 
state of residence. PEDSF file has been linked with Medicare data files using an algorithm based 
on the social security number, last name, first name and date of birth of an individual. Medicare 
claims files consists of Medicare Provider Analysis and Review (MEDPAR), the Carrier Claims 
(old name Physician/Supplier (NCH)), Outpatient (OUTPT), Home Health Agencies (HHA), 
Hospice, Durable Medical Equipment (DME) and Part D Event (PDE) files. Based on the 
linkage, a common identification number is given to each enrollee in PEDSF and claims files. 
We also linked the Area Resource File (ARF) to the SEER-Medicare dataset using the state and 
county Federal Information Processing Standards code for each beneficiary to extract the county 
level information on the availability of mammography facilities and oncology centers in 
women’s area of residence.  
Study Cohort 
The study was conducted in a cohort of women of 67 years or older with the first primary 
diagnosis of incident BC between January 1, 2007 and December 31, 2011 who had pre-existing 
diabetes. Figure 1 shows the flow chart to obtain final study cohort. Eligible Medicare 
beneficiaries were continuously enrolled in Medicare Part A and B fee-for-service programs at 
least 24 months before BC diagnosis and 6 months after BC diagnosis, and they were 
continuously enrolled in Part D at least 3 months after BC diagnosis. Also, they must have no 
enrollment in health maintenance organization (HMO) at any time during the study period. Pre-
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existing diabetes was determined based on either a single inpatient claim or at least two 
outpatient claims diagnoses with International Classification of Diseases, Ninth Edition, Clinical 
Modification (ICD-9-CM) diagnosis code of 250.xx during the 24-month that preceded BC 
diagnosis. Women whose BC was diagnosed via a death certificate or autopsy, or who were with 
any previous cancer diagnosis were excluded from the study cohort.  
Measures  
 Outcome variable   
The study outcome was all-cause mortality that included breast cancer-specific mortality, 
diabetes-specific mortality and mortality from other causes (Patnaik et al., 2011). All-cause 
mortality is the most commonly used outcome for research on cancer survivorship (Patnaik et al., 
2011) because it is not affected by bias in classifying cause of death in comparison to disease-
specific mortality (Black, Haggstrom, & Welch, 2002; Hanna et al., 2012). The study cohort was 
followed to death or to the end of third year after BC diagnosis, whichever occurred first. 
Observations were censored for women who were alive more than 3 years after BC diagnosis.  
Key independent variable 
The main predictor of all-cause mortality in this study was the diabetes severity which 
was identified during the 12 months before BC diagnosis. The severity of diabetes-related 
complications was measured by end-organ damage of diabetes using the diabetes comorbidity 
severity index (DCSI). The DCSI was first developed by Young and colleagues to include 7 
categories of diabetes complications: cardiovascular disease, nephropathy, retinopathy, 
peripheral vascular disease, cerebrovascular, neuropathy, and metabolic complications. Theses 
complications were identified using International Classification of Diseases, Ninth Edition, 
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Clinical Modification (ICD-9-CM) diagnosis code to represent gradations of the diabetes 
complications severity (Young et al., 2008). The index for each complication was categorized 
into 2 or 3 levels (no abnormality = 0, some abnormality = 1, and severe abnormality = 2), based 
on the presence and severity of the complication, and the indices of all complications were added 
together to get the DCSI which is a 13-point scale with a range of 0-13 (Chang et al., 2012a; 
Young et al., 2008). The study cohort was divided into 4 subgroups consisting of DCSI=0, 
DCSI=1, DCSI=2, and DCSI ≥ 3. 
Other independent variables  
The variables were classified based on the model of comorbidity and cancer into the 
characteristics of incident BC, patient’s factors, and cancer treatment.  
The characteristics of incident BC are BC stage at diagnosis and HR status. Stage of BC at 
diagnosis was identified based on the American Joint Committee on Cancer's staging system. Stage 
at diagnosis (0-IV) of the cancer/tumor was taken from the SEER PEDSF file. For the study 
purpose, we grouped out cohorts into two categories: women with early stage diagnosis (stages 0, 
I & II) and women with advanced stage diagnosis (stages III & IV) of BC. HR status (progesterone 
and estrogen) was categorized into positive, negative, and borderline/unknown. 
 Patient factors included age at diagnosis, race, SEER areas, metropolitan status, Census 
tract education percentage, Census tract median household income, pre-existing comorbidities, 
and diabetes medications. Age was categorized into 67–70, 71-74, 75-79, and 80+. Race was 
categorized into white, African-American, and others. SEER regions were Northeast, South, 
North Central, and West.  Metropolitan status of patients’ residence was classified as metro, 
urban, and rural. Census tract education percentage was measured by the census tract survey of 
percent of people age > 25 with at least 4 years of college education. Census tract education 
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percentage was divided into four categories: 0-13.29%, 13.30%-22.83%, 22.84%-38.55%, and 
>38.55%. Income was measured by census tract survey of median income and was also divided 
into four categories: <$25,000, $25,001-50,000, $50,001-75,000, and >$75,000. Pre-existing 
comorbidities was identified during the 12 months before BC diagnosis through the presence or 
absence of the certain chronic conditions: thyroid syndrome, arthritis, asthma, chronic 
obstructive pulmonary disorder (COPD), dementia, hyperlipidemia, hypertension, osteoporosis, 
anxiety, and depression. We also include antidiabetic medications: metformin use (yes/no), 
insulin use (yes/no), and sum of other oral diabetes medications (ODMs) (0, 1, or ≥ 2 
medications). These other diabetes medications included sulfonylureas, thiazolidinediones, 
meglitinides, alpha-glucosidase, glucagonlike peptide-1 agonists, dipeptidyl peptidase IV 
inhibitors, amylinomimetics, bile acid sequestrates, and dopamine agonists. Women were 
defined as users of any of diabetes medication including insulin, metformin and ODMs during 
the baseline period if they had ≥ 1 dispensing of a medication during the first 3 months after the 
incident BC diagnosis.  These medications were identified from Part D claims using generic 
names.  
Cancer treatment was identified from MEDPAR, Outpatient, and NCH data files using 
ICD-9 diagnostic and procedure, and Current Procedural Terminology/ Healthcare Common 
Procedure Coding System (CPT/HCPCS) which was discussed in previous research (LeMasters, 
Madhavan, & Sambamoorthi, 2016) . These codes were used to determine whether a woman had 
received chemotherapy, radiation or had undergone any surgery within 180 days from the date of 
BC diagnosis. We also controlled for primary care providers (PCPs) visits, endocrinologist visits, 
and oncologist visits. We defined PCPs as providers who had the following specialties: general 
practice, family medicine, primary care internal medicine, geriatric medicine, and obstetrics and 
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gynecology. PCPs visits, endocrinologist visits, and oncologist visits were measured during the 6 
months after BC diagnosis.  PCPs visits and endocrinologist visits were categorized into 
dichotomous group: yes (having at least one visit during the 6 months after BC diagnosis) or no. 
Oncologist visits was divided into 0-10, 11-20, and ≥ 20 visits.  
Statistical Analyses  
Descriptive analyses were performed for all study variables as mean and standard 
deviation (SD) or frequencies and percentages. Chi-square tests of general associations were 
used to test for significant group differences between independent measures and women who 
were dead or alive 3 years after BC diagnosis, with significance level at P ≤ 0.05. Cox 
proportional hazards regression models were used to estimate the risk of death at any time within 
3 years of BC diagnosis based on the index of diabetes-related complications, adjusting for other 
independent variables. Patients with incident BC and pre-existing diabetes were considered at 
risk from baseline (the 12-months period that preceded BC diagnosis), and then they were 
followed till the death or the end of third year whichever comes first. Parameter estimates 
calculated in the regression models were presented as unadjusted and adjusted hazard ratios (HR) 
with their corresponding 95% confidence intervals (CI). All analyses were conducted using SAS 
version 9.4 software (SAS Institute Inc., Cary, NC). 
RESULTS 
Cohort Characteristics 
Among elderly women with incident BC (2007-2011) and pre-existing diabetes, the 
average time-to-death was 874.61 (SD = ± 535.63) days and the average diabetes complications 
severity index was 1.46 (SD = ± 1.76). Characteristics of the 4,307 women with incident BC and 
pre-existing diabetes are described in details in Table 1. The majority of women in the cohort 
were white (73.8%), diagnosed with early stages (0, I, & II) of BC (85.1%), had no diabetes 
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complications (45.8%), had positive progesterone HR status (65.0%) and positive estrogen HR 
status (76.4%), lived in metro areas (77.8%), lived in areas with availability of oncology 
treatment centers (68.9%), lived in areas where the average annual income was greater than 
$25,000 (90.0%), and lived in areas where 13.3% or more of the population was college 
educated (72.6%). Regarding pre-existing comorbidities, most of the women had hyperlipidemia 
(69.9%), and hypertension (87.7%), while 27.4% had arthritis, 23.8% had thyroid syndrome, 
15.3% had depression, 14.6% had COPD, 10.1% had anxiety, 8.4% had asthma, 8.3% had 
dementia, and 7.8% had osteoporosis. For the visits to physicians in the first 6 months after BC 
diagnosis, most women had at least one PCP visit (78.3%), had at least 11 oncologist visits 
(75.6%), and had no endocrinologist visit (90.8%). The most frequent diabetes-related 
complications were cardiovascular complications (39.6%), nephropathy (17.9%), neuropathy 
(11.9%), while metabolic complications (0.7%), retinopathy (4.4%), cerebrovascular 
complications (7.4%), and peripheral vascular disease (8.5%) were less frequent among incident 
cases of BC with pre-existing diabetes.  Most of women with incident BC and pre-existing 
diabetes had received surgical treatment in the first 6 months after BC diagnosis (86.0%), 36% 
had received radiation while only 18% had received chemotherapy. There were 1021 (23.7%) 
women who used insulin in the first 3 months after BC diagnosis, 1490 (34.6%) used metformin, 
and 1744 (40.5%) used at least one of the other oral diabetes medications. Compared with 
women who had no diabetes complications (DCSI=0), those with DCSI ≥ 3 were older, more 
likely to use insulin, less likely to use metformin, less likely to use ODMs, less likely to receive 
radiotherapy, more likely to have PCP visits, and more likely to have other pre-existing 
comorbid conditions (thyroid syndrome, arthritis, COPD, dementia, hypertension, and 
depression).   
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Group Differences by 3-Year Mortality 
Table 2 shows the group differences in all the independent variables by 3-year mortality. 
Among a cohort of women with incident BC and pre-existing diabetes, 21.8% died by the end of 
three years after BC diagnosis. The variables that were significantly different between women 
who died within 3 years after BC diagnosis, and those who were alive by the end of the third 
year included severity of diabetes-related complications, insulin use, metformin use, age, race, 
stage of BC at diagnosis, HR status, chemotherapy reception, radiation reception, surgery, 
endocrinologist visit, number of oncologists visits, availability of oncology treatment centers, 
and SEER regions. The pre-existing comorbid conditions that were significantly associated with 
3-year all-cause mortality included asthma, COPD, dementia, hyperlipidemia, anxiety, and 
depression.  
Severity of Diabetes Complications and 3-year All-cause Mortality  
Among women who died within the first 3 years after BC diagnosis, a higher proportion 
(37.6%) had highest severity of diabetes complication (DCSI ≥ 3) as compared to those who 
were still alive 3 years after BC diagnosis (17.3%). In contrast, a lower proportion of women 
who died within 3 years after BC diagnosis were without diabetes complications as compared to 
those who were still alive 3 years after BC diagnosis (29.4% vs. 50.4%).  
Other independent variables and 3-year All-cause Mortality  
Among women who died within three years after BC, the percentage of those who were 
diagnosed at late stages (III/IV) of BC was higher than those who were still alive three years 
after BC diagnosis (35.3% vs. 9.8%). The percentages of women with positive progesterone HR 
status (50.9%) or positive estrogen HR status (62.6%) were lower among women who died with 
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three years after BC diagnosis as compared to women who were still alive three years after BC 
diagnosis (68.9% and 80.3% respectively). A higher proportion of women who died within 3 
years after BC diagnosis were insulin users as compared to those who were still alive three years 
after BC diagnosis (34.8% vs. 20.6%). In contrast, a lower proportion of women who died within 
3 years after BC diagnosis were metformin user as compared to those who were still alive three 
years after BC diagnosis (22.6% vs. 37.9%).  For other oral diabetes medications, there was no 
significant association between the number of medications and all-cause mortality. Among 
women who were alive three years after BC diagnosis, the proportion of women who had 
received surgery (91.6% vs. 66%) or radiation (41.7% vs. 19.3%) was higher than those who 
died with the first three years after BC diagnosis. Women who died within three years after BC 
diagnosis were more likely to have pre-existing COPD, dementia, and depression and were less 
likely to have hyperlipidemia as compared to those who were alive three years after BC 
diagnosis.     
Risk of Death within 3 Years of Diagnosis 
Results from multivariable analyses of incident BC cases with pre-existing diabetes are 
shown in table 3. In the unadjusted analyses (model 1), there was a significant association 
between severity of diabetes complications and risk of all-cause mortality. Women who had a 
severity of diabetes complications with DCSI = 2 & DCSI ≥ 3 were 2.06 (HR = 2.06; 95% CI = 
1.70-2.48) and 3.30 (HR = 3.30; 95% CI = 2.78-3.92) times respectively, more likely to die 
within 3 years of BC diagnosis, than women with no diabetes complications.    
In Model 2, severity of diabetes-related complications was significantly associated with 
the risk of all-cause mortality after controlling for diabetes medications, cancer treatment, HR 
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status, race, age, and other pre-existing comorbid conditions. A severity of diabetes 
complications with DCSI =1, DCSI =2, and DCSI ≥3 was associated with 33% (HR = 1.22; 95% 
CI = 1.01-1.74), 67% (HR = 1.67; 95% CI = 1.38-2.03), and 127% (HR = 2.27; 95% CI = 1.89-
2.73) increase in risk of death, respectively, within 3 years after BC diagnosis as compared to 
those without diabetes complications.  
In Model 3, severity of diabetes-related complications was still significantly associated 
with the risk of all-cause mortality after controlling for diabetes medications, cancer treatment, 
HR status, race, age, other pre-existing comorbid conditions, and SEER regions. Women with 
DCSI =1, DCSI =2, and DCSI ≥3 had 34% (HR = 1.34; 95% CI = 1.02-1.75), 69% (HR = 1.69; 
95% CI = 1.39-2.05), and 124% (HR = 2.24; 95% CI = 1.86-2.70) increased risk of death within 
3 years after BC diagnosis, respectively, as compared to those without diabetes complications. 
Women who used insulin had 58% (HR = 1.58; 95% CI = 1.35-1.84) increased risk of death, 
compared to those who did not use insulin after controlling for diabetes severity, other diabetes 
medications, cancer treatment, cancer characteristics, and other patient’s factors. Conversely, 
women who used metformin had 26% (HR = 0.74; 95% CI = 0.63-0.88) decreased risk of death, 
compared to those who did not use metformin after controlling for diabetes severity, other 
diabetes medications, cancer treatment, cancer characteristics, and other patient’s factors.  
In addition, women who received radiation therapy within the first 6 months after BC 
diagnosis had 37% (HR = 0.63; 95% CI = 0.52-0.76) decreased risk of death, compared to 
women who did not receive any radiation therapy after controlling for cancer characteristics, 
patient’s factors, diabetes severity, and diabetes medications. Women receiving surgery within 
the first 6 months after BC diagnosis had a 55% (HR = 0.45; 95% CI = 0.38-0.53) decrease in 
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the risk of death, compared to women who having no surgery after adjusting for cancer 
characteristics, patient’s factors, diabetes severity, and diabetes medications. 
Women with progesterone HR & estrogen HR positive tumors had a 26% (HR = 0.74; 
95% CI, 0.60, 0.92) and 38% (HR = 0.62; 95% CI, 0.49, 0.79) decrease in the risk of death 
within three years of diagnosis respectively, then women with progesterone HR & estrogen HR 
negative tumors.  
Further, women who had ≥ 20 oncologist visits during the first 6 months were 1.39 (HR = 
1.39; 95% CI = 1.12-1.72) times more likely to die within 3 years of BC diagnosis, compared to 
women who had a maximum of 10 oncologist visits. Also, having at least one endocrinologist 
visit during the first 6 months was associated with 25% (HR=0.75; 95% CI=0.56-0.98) decrease 
in the risk of death within 3 years of BC diagnosis as compared to women who do not have any 
endocrinologist visit.          
DISCUSSION 
Overall Findings  
The main finding of this study is that severity of diabetes-related complications is 
independently associated with all-cause mortality among elderly women with incident BC and 
pre-existing diabetes, irrespective of diabetes medication, other comorbidities, cancer 
characteristics, cancer treatment, and other patient-related factors. Women with a DCSI =1 had a 
34% increased risk of death, women with a DCSI =2 had a 69% increased risk of death, and 
women with a DCSI ≥3 had a 124% increased risk of death within 3 years of BC diagnosis as 
compared to those without diabetes complications. This indicated that as the severity of diabetes 
complication increases, the risk of mortality increases. Also, this finding shows that having any 
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diabetes complications is significantly associated with increased risk of all-cause mortality as 
compared to women without diabetes complications.   
Previous studies have revealed women with diabetes have a higher risk of mortality, 
compared to women without diabetes (Lipscombe et al., 2008; Luo et al., 2015; Verlato et al., 
2003). However, to the best of our knowledge, no research has investigated the influence of 
diabetes complications severity on the high rates of mortality among incident BC cases using an 
established index. Thus, this study expands the existing literature by showing in a large 
population the impact of biological factors and severity of diabetes measured by end-organ 
damage on this association after controlling for a comprehensive list of factors that could 
contribute to this association. Studies have shown the significance of using DCSI as a measure of 
diabetes severity to predict costs, health resource utilizations, hospitalization, and mortality 
among individuals with diabetes (Chang et al., 2012; Hazel-Fernandez et al., 2015; Young et al., 
2008). However, when it comes to cancer prognosis, many biological factors become less 
important as compared to cancer severity and cancer treatment (Battafarano et al., 2002; Bugge 
et al., 2016; Shavers & Brown, 2002). Our findings revealed that DCSI was a significant 
predictor of all-cause mortality among women with incident BC diagnosis even after controlling 
for diabetes medications, cancer characteristics, cancer treatment, and other patient-related 
factors.  
A study by Young et al showed that in adjusted analyses, having a DCSI =1 or a DCSI = 
2 was not significantly associated with risk of all-cause mortality among individual with diabetes 
while having a DCSI ≥3 was associated with all-cause mortality (Young et al., 2008). However, 
our study showed that among a cohort of women with incident BC and pre-existing diabetes, the 
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association between the severity of diabetes complications and all-cause mortality is significant 
starting from a DCSI=1.           
Diabetes Medications, Endocrinologist visits & All-cause Mortality 
  In addition to severity of diabetes, using insulin and/or metformin was significantly 
associated with all-cause mortality after controlling for all possible factors. Metformin use was 
significantly associated with a 26% decrease in risk of death within three years of BC diagnosis. 
In contrast, a recent meta-analysis of randomized controlled trials (RCT) data showed that there 
is no significant impact of metformin on all-cause mortality among individuals with diabetes and 
cancer (Stevens et al., 2012). However, lack of adjusted estimates, heterogeneity of trials, and 
certain sources of bias could weaken the conclusion regarding the lack of significant impact of 
metformin on survival rates among cancer patients who had pre-existing diabetes. Also, a study 
conducted in Canada among elderly women with incident BC cancer and pre-existing diabetes 
found that there is no association between metformin use and survival rate (Lega et al., 2013).  
Although some of these studies accounted for cancer treatment, other diabetes 
medications, and/or comorbidity, none of them they controlled for diabetes severity and cancer 
stage which have significant effects on all-cause mortality, and may have biased the results 
(Holman, 2007). Therefore, by including a comprehensive list of potential predictors including 
cancer severity and diabetes severity in our multivariable analyses, our results provided a robust 
evidence about the positive impact of metformin use on health outcomes of incident BC cases 
with pre-existing diabetes.       
Insulin use was significantly associated with 58% increase in hazard of death within 3 
years of BC diagnosis as compared to women who did not use insulin. Generally, insulin helps 
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the body to regulate the level of blood glucose and helps cells grow, but people with diabetes and 
obesity usually have high insulin levels (hyperinsulinemia) because their bodies are not sensitive 
to insulin (insulin-resistance) (Mokdad et al., 2003; Schwartz & Porte, 2005). Many studies have 
linked the pathophysiology of insulin-resistance to a worse prognosis of BC among obese 
patients with pre-existing diabetes (Duggan et al., 2011; Goodwin, 2015). Although we 
controlled for many diabetes-related factors and cancer-related factors, we did not control for 
obesity which is a possible covariate in this association.  
In addition to diabetes medications, endocrinologist visits during the first 6 months of BC 
diagnosis was a significant predictor of all-cause mortality. Having at least one endocrinologist 
visits within the first 6 months of BC diagnosis was significantly associated with 26% decrease 
in all-cause mortality. A previous study suggested that endocrinologist visits provide a better 
understanding of diabetes and its complications which may have a substantial impact on 
improvements in glycemic control for poorly controlled diabetes (Salti et al., 2011). However, 
few incident BC cases and pre-existing diabetes are seen by an endocrinologist (Oppong et al., 
2014). In our study, only 398 (9.2%) out of 4307 women with incident BC and pre-existing 
diabetes had seen an endocrinologist during the first 6 months of BC diagnosis. Our findings 
showed that contribution of endocrinologists in health care of incident BC cases with pre-
existing diabetes may help in improving health outcomes and reducing the risk of death after BC 
diagnosis. Therefore, our study suggests a comprehensive team approach including 
endocrinologists for patients with BC and pre-existing diabetes to control diabetes and severity 
of diabetes-related complications, and thereby reduce their impact on cancer outcomes.  
Cancer Treatment and All-cause Mortality 
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For cancer treatment, a high proportion (86.2%) of the study cohort were treated with 
surgery within the first 6 months of BC diagnosis, 36% received radiation while a low proportion 
received chemotherapy (18.0%). This was consistent with previous research that indicated that 
elderly women with BC and diabetes are less likely to receive chemotherapy as compared to 
those without diabetes due to increased risk of chemotherapy-related toxicities compared with 
nondiabetic patients (Gold et al., 2014; Srokowski et al., 2009).  
With respect to the adjusted association with all-cause mortality, our results showed that 
surgery and radiotherapy were associated with 55% and 37% decrease in the risk of all-cause 
mortality, respectively, within three years of BC diagnosis while there was no significant 
association between chemotherapy and all-cause mortality. Similar to previous research, 
radiotherapy use was associated with an improvement in overall survival among incident BC and 
pre-existing diabetes (Lega et al., 2013). However, our results regarding surgery and all-cause 
mortality were  not consistent with previous studies that showed that women with diabetes were 
more likely to die within a few months following  surgery  than those without diabetes 
(Plodkowski & Edelman, 2001). In our study, after we controlled for insulin use, other diabetes 
medications, severity of diabetes complications, stage of BC, and all other possible factors, we 
found that surgery was associated with improvement in survival among women with diabetes as 
compared to women who did not received surgery.  
Unlike previous research that suggested that receipt of chemotherapy may be associated 
with an increased risk of death (Alenzi & Kelley, 2017; Brunello, Kapoor, & Extermann, 2011; 
Crawford et al., 2008; Lega et al., 2013; Matias Cdo et al.,  2013; Peairs et al., 2011), our 
findings revealed that chemotherapy was not associated with all-cause mortality after controlling 
for diabetes severity, cancer severity and all other possible covariates.  This may indicate that the 
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association between chemotherapy-related toxicity and mortality is mediated by diabetes severity 
since all the previous studies did not control for diabetes severity. 
Strengths and Limitations 
This study has several potential limitations that should be considered when interpreting 
the results. First, we lacked data on some biological factors, such as obesity which could have 
residual confounding effect on the risk of mortality. Second, individuals within the SEER-
Medicare data tend to be more urban and affluent and with higher concentrations of racial and 
ethnic minorities, as compared to the US population (Warren et al., 2002). Third, since we used a 
claims database instead of medical records to measure DSCI, the index was measured without 
laboratory results. However, a study by Chang et al. tested the validity of DCSI without 
laboratory results and they found that the DCSI without laboratory results and the DCSI with 
laboratory information perform similarly (Chang et al., 2012b). Fourth, socio-demographic 
characteristics such as income and education were aggregate census level measures, rather than 
individual level measures. Since we included elderly women who were continuously enrolled in 
Medicare part D for three months, we could not identify the reception of oral therapies, such as 
oral chemotherapy (e.g. tamoxifen) during the first 6 months that followed BC screening. Other 
limitations include lack of other biological information, such as blood glucose level, glycosylated 
hemoglobin A1c lab results, and diabetes duration. 
Despite the potential limitations, the current study has many strengths. First, using a valid 
and reliable index to measure diabetes severity which enabled us to capture the severity of the 
disease and its-related complications, assessing its impact on all-cause mortality, and controlling 
for diabetes severity to assess the adjusted association of other factors with all-cause mortality. 
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To assess the severity of diabetes-related complications, we used DCSI which captures both the 
type and severity of diabetes complications while a simple count of complications does not take 
the severity of each complication into account (Young et al., 2008). In addition to its use as 
measure of diabetes severity, a study by Young et al. found that this index may be considered as 
a proxy measure for diabetes duration (Young et al., 2008). Young et al found that severity index 
of diabetes complications was highly correlated with diabetes duration, and it attenuated the 
significant impact of diabetes duration on mortality after it was added to the analysis model 
(Young et al., 2008).  Because diabetes may remain undiagnosed for years, using DCSI as a 
severity measure of long- term complications probably demonstrates the consequences of 
biologic markers of diabetes duration (Harris & Eastman, 2000).   
In conclusion, both existence and severity of diabetes-related complications are 
independently associated with all-cause mortality among elderly women with incident BC and 
pre-existing diabetes as compared to women without diabetes complications. It is essential that 
incident BC cases with pre-existing diabetes medications receive optimal diabetes care along 
with cancer therapy through a close collaboration between oncologists and endocrinologists.   
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Figure 1: Study Cohort Selection Flowchart 
 
 
 
 
  
Women who diagnosed with breast cancer in SEER from 
January 01, 2007 to December 31, 2011                        
(N= 169,955) 
Diagnosed with Primary breast cancer                             
(N= 130,698) 
Excluded (N=39,257)                                            
Breast cancer was diagnosed as a secondary cancer or 
there are other types of cancer    
Incident cases of primary breast cancer                         
(N= 130,038) 
Excluded (N=660)                                                 
Breast cancer was not an incident case 
Breast cancer was not diagnosed at autopsy or death             
(N= 129,206) 
Excluded (N=832)                                                 
Breast cancer was diagnosed at autopsy or death 
Aged ≥ 67                                                                                  
(N= 76,123) 
Excluded (N=53,083)                                                
Aged < 67 
Continuous enrollment in part A & B and no HMO enrollment at 
least 24 months before breast cancer diagnosis                           
(N= 45,977) 
Excluded (N=30,146)                                                   
No continuous enrollment in part A & B and no HMO 
enrollment at least 24 months before breast cancer 
diagnosis   
Excluded (N=19,727)                                                  
No continuous enrollment in part D at least 3 months 
after breast cancer diagnosis  
Continuous enrollment in part D at least 3 months after breast 
cancer diagnosis                                                                           
(N= 26,250) 
Diagnosed with diabetes before breast cancer diagnosis                                                                                       
(N= 4,307) 
Excluded (N=21,943)                                                
Were not diagnosed with diabetes before breast cancer 
diagnosis 
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Table 1: The Characteristics of the Study Cohort* by Diabetes Complications Severity Index 
 
All Women, 
N=4307  
DCSI=0, 
N= 1972 
DCSI=1, 
N= 496 
DCSI=2, 
N= 902 
DCSI≥3, 
N= 937  
Characteristics No. % No. % No. % No. % No. % 
Insulin use           
 Yes 1021 23.7 323 16.4 109 22.0 226 25.1 363 38.7 
 No  3286 76.3 1649 83.6 387 78.0 676 74.9 574 61.3 
Metformin use          
 Yes 1490 34.6 833 42.2 209 42.1 252 27.9 196 20.9 
 No 2817 65.4 1139 57.8 287 57.9 650 72.1 741 79.1 
Other diabetes medications          
 0 2563 59.5 1165 59.1 285 57.5 528 58.5 585 62.4 
 1 1403 32.6 637 32.3 168 33.9 301 33.4 297 31.7 
 ≥ 2 341 7.9 170 8.6 43 8.7 73 8.1 55 5.9 
Age            
 67-70 938 21.8 470 23.8 133 26.8 154 17.1 181 19.3 
 71-74 1155 26.8 572 29.0 137 27.6 234 25.9 212 22.6 
 75-79 818 19.0 371 18.8 86 17.3 171 19.0 190 20.3 
 >=80 1396 32.4 559 28.3 140 28.2 343 38.0 354 37.8 
Race           
 White 3180 73.8 1479 75.0 364 73.4 689 76.4 648 69.2 
 African American 724 16.8 283 14.4 77 15.5 134 14.9 230 24.5 
 Others 403 9.4 210 10.6 55 11.1 79 8.8 59 6.3 
Stage at diagnosis          
 Early stage 3435 85.1 1600 85.7 406 86.6 715 84.9 714 83.4 
 Advanced stage 600 14.9 268 14.3 63 13.4 127 15.1 142 16.6 
Progesterone receptor status          
 Positive 2798 65.0 1297 65.8 335 67.5 592 65.6 574 61.3 
 Negative 1057 24.5 494 25.1 115 23.2 207 22.9 241 25.7 
 Borderline/Unknown 452 10.5 181 9.2 46 9.3 103 11.4 122 13.0 
Estrogen receptor status            
 Positive 3291 76.4 1549 78.5 376 75.8 692 76.7 674 71.9 
 Negative 611 14.2 267 13.5 77 15.5 118 13.1 149 15.9 
 Borderline/Unknown 405 9.4 156 7.9 43 8.7 92 10.2 114 12.2 
Had chemotherapy   
        
 Yes 776 18.0 387 19.6 94 19.0 146 16.2 149 15.9 
 No 3531 82.0 1585 80.4 402 81.0 756 83.8 788 84.1 
Had radiation           
 Yes 1586 36.8 818 41.5 196 39.5 321 35.6 251 26.8 
 No 2721 63.2 1154 58.5 300 60.5 581 64.4 686 73.2 
Had any surgery           
 Yes 3705 86.0 1745 88.5 448 90.3 754 83.6 758 80.9 
 No 602 14.0 227 11.5 48 9.7 148 16.4 179 19.1 
Thyroid syndrome           
 Yes  1024 23.8 388 19.7 135 27.2 246 27.3 255 27.2 
 No  3283 76.2 1584 80.3 361 72.8 656 72.7 682 72.8 
Arthritis   
        
 Yes 1182 27.4 461 23.4 156 31.5 264 29.3 301 32.1 
 No  3125 72.6 1511 76.6 340 68.5 638 70.7 636 67.9 
Asthma           
 Yes 361 8.4 126 6.4 33 6.7 103 11.4 99 10.6 
 No  3946 91.6 1846 93.6 463 93.3 799 88.6 838 89.4 
…Continued            
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Table 1: The Characteristics of the Study Cohort* by Diabetes Complications Severity Index 
 
All Women, 
N=4307  
DCSI=0, 
N= 1972 
DCSI=1, 
N= 496 
DCSI=2, 
N= 902 
DCSI≥3, 
N= 937  
Characteristics No. % No. % No. % No. % No. % 
COPD           
 Yes 630 14.6 158 8.0 45 9.1 183 20.3 244 26.0 
 No  3677 85.4 1814 92.0 451 90.9 719 79.7 693 74.0 
Dementia           
 Yes  358 8.3 111 5.6 34 6.9 77 8.5 136 14.5 
 No  3949 91.7 1861 94.4 462 93.1 825 91.5 801 85.5 
Hyperlipidemia           
 Yes  3010 69.9 1318 66.8 371 74.8 638 70.7 683 72.9 
 No  1297 30.1 654 33.2 125 25.2 264 29.3 254 27.1 
Hypertension           
 Yes  3776 87.7 1589 80.6 445 89.7 836 92.7 906 96.7 
 No  531 12.3 383 19.4 51 10.3 66 7.3 31 3.3 
Osteoporosis           
 Yes  337 7.8 146 7.4 41 8.3 82 9.1 68 7.3 
 No  3970 92.2 1826 92.6 455 91.7 820 90.9 869 92.7 
Anxiety           
 Yes  435 10.1 143 7.3 62 12.5 114 12.6 116 12.4 
 No  3872 89.9 1829 92.7 434 87.5 788 87.4 821 87.6 
Depression           
 Yes 657 15.3 210 10.6 72 14.5 170 18.8 205 21.9 
 No  3650 84.7 1762 89.4 424 85.5 732 81.2 732 78.1 
PCP visit           
 Yes 3374 78.3 1505 76.3 384 77.4 727 80.6 758 80.9 
 No 933 21.7 467 23.7 112 22.6 175 19.4 179 19.1 
Endocrinologist visit           
 Yes 398 9.2 156 7.9 55 11.1 76 8.4 111 11.8 
 No 3909 90.8 1816 92.1 441 88.9 826 91.6 826 88.2 
# of oncologists visits           
 0-10 1051 24.4 524 26.6 116 23.4 198 22.0 213 22.7 
 11-20 1705 39.6 794 40.3 193 38.9 365 40.5 353 37.7 
 ≥ 20 1551 36.0 654 33.2 187 37.7 339 37.6 371 39.6 
Availability of oncology centers         
 Yes 2967 68.9 1362 69.1 338 68.1 623 69.1 644 68.7 
 No 1340 31.1 610 30.9 158 31.9 279 30.9 293 31.3 
Census tract education   
        
 0-13.29% 1179 27.4 496 25.2 134 27.1 269 29.9 280 29.9 
 13.30%-22.83% 1288 30.0 608 30.9 133 26.9 258 28.6 289 30.9 
 22.84%-38.55% 969 22.6 429 21.8 120 24.2 206 22.9 214 22.9 
 >38.55% 860 20.0 432 22.0 108 21.8 168 18.6 152 16.3 
Census tract household income          
 < $25,000 305 7.1 132 6.7 36 7.3 55 6.1 82 8.8 
 $25,001-50,000 1882 43.7 809 41.0 219 44.2 410 45.5 444 47.4 
 $50,001-75,000 1338 31.1 651 33.0 147 29.6 278 30.8 262 28.0 
 >$75,000 782 18.2 380 19.3 94 19.0 159 17.6 149 15.9 
SEER region           
 Northeast 805 18.7 373 18.9 96 19.4 171 19.0 165 17.6 
 South 1280 29.7 529 26.8 137 27.6 279 30.9 335 35.8 
 North-central 658 15.3 307 15.6 81 16.3 115 12.7 155 16.5 
 West 1564 36.3 763 38.7 182 36.7 337 37.4 282 30.1 
…Continued            
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Table 1: The Characteristics of the Study Cohort* by Diabetes Complications Severity Index 
 
All Women, 
N=4307  
DCSI=0, 
N= 1972 
DCSI=1, 
N= 496 
DCSI=2, 
N= 902 
DCSI≥3, 
N= 937  
Characteristics No. % No. % No. % No. % No. % 
Metropolitan status           
 Metro 3347 77.8 1532 77.8 392 79.0 685 76.0 738 78.8 
 Urban 824 19.1 379 19.2 86 17.3 188 20.9 171 18.2 
 Rural 132 3.1 58 2.9 18 3.6 28 3.1 28 3.0 
            
*A cohort of 4,307 elderly women with incident breast cancer and pre-existing diabetes using SEER-Medicare 
dataset 2007-2011. 
DCSI = Diabetes complications severity index; PCP = Primary care providers;  
COPD = Chronic Obstructive Pulmonary Disorder; SEER = Surveillance, Epidemiology, and End Results; BC = 
Breast cancer. 
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Table 2: Description of Elderly Women with Incident Breast Cancer and Pre-
existing Diabetes by 3-Year All-cause Mortality, SEER-Medicare 2007–2011  
Variables Dead Alive 
 
 
N % N % sig 
Total 939 100 3368 100  
DCSI 
     
***  
DCSI = 0 276 29.4 1696 50.4 
 
 
DCSI = 1 77 8.2 419 12.4 
 
 
DCSI = 2 233 24.8 669 19.9 
 
 
DCSI ≥ 3 353 37.6 584 17.3 
 
Insulin use in 3 Months after BC Diagnosis 
  
*** 
 
Yes 327 34.8 694 20.6 
 
 
No  612 65.2 2674 79.4 
 
Metformin Use in 3 Months after BC Diagnosis   *** 
 Yes 212 22.6 1278 37.9  
 No 727 77.4 2090 62.1  
Other Diabetes Medication      
 0 579 61.7 1984 58.9  
 1 295 31.4 1108 32.9  
 ≥ 2 65 6.9 276 8.2  
Age group 
    
***  
67-70 129 13.7 809 24.0 
 
 
71-74 170 18.1 985 29.2 
 
 
75-79 170 18.1 648 19.2 
 
 
>=80 470 50.1 926 27.5 
 
Race 
     
***  
White 689 73.4 2491 74.0 
 
 
African American 193 20.6 531 15.8 
 
 
Others 57 6.1 346 10.3 
 
Stage of BC at Diagnosis     *** 
 Early stage 518 64.7 2917 90.2  
 Advanced stage 283 35.3 317 9.8  
Progesterone receptor status 
   
***  
Positive 478 50.9 2320 68.9 
 
 
Negative 304 32.4 753 22.4 
 
 Borderline/Unknown 157 16.7 295 8.8  
Estrogen receptor status   
   
*** 
 
Positive 588 62.6 2703 80.3 
 
 
Negative 203 21.6 408 12.1 
 
 Borderline/Unknown 148 15.8 257 7.6  
Had Chemotherapy     * 
 Yes 194 20.7 582 17.3  
 No 745 79.3 2786 82.7  
Had Radiation     *** 
 Yes 181 19.3 1405 41.7  
 No 758 80.7 1963 58.3  
Had any Surgery     *** 
 Yes 620 66.0 3085 91.6  
 No 319 34.0 283 8.4  
Thyroid Syndrome       
Yes  229 24.4 795 23.6 
 
 
No 710 75.6 2573 76.4 
 
...Continued      
106 
 
Table 2: Description of Elderly Women with Incident Breast Cancer and Pre-
existing Diabetes by 3-Year All-cause Mortality, SEER-Medicare 2007–2011  
Variables Dead Alive 
 
 
N % N % sig 
Arthritis 
      
 
Yes  262 27.9 920 27.3 
 
 
No  677 72.1 2448 72.7 
 
Asthma 
     
*  
Yes  64 6.8 297 8.8 
 
 
No 875 93.2 3071 91.2 
 
COPD 
     
***  
Yes  229 24.4 401 11.9 
 
 
No  710 75.6 2967 88.1 
 
Dementia 
    
***  
Yes  173 18.4 185 5.5 
 
 
No  766 81.6 3183 94.5 
 
Hyperlipidemia 
    
***  
Yes  538 57.3 2472 73.4 
 
 
No  401 42.7 896 26.6 
 
Hypertension 
     
 
Yes  840 89.5 2936 87.2 
 
 
No 99 10.5 432 12.8 
 
Osteoporosis  
     
 
Yes  66 7.0 271 8.0 
 
 
No  873 93.0 3097 92.0 
 
Anxiety 
    
*  
Yes  115 12.2 320 9.5 
 
 
No  824 87.8 3048 90.5 
 
Depression 
    
***  
Yes  205 21.8 452 13.4 
 
 
No  734 78.2 2916 86.6 
 
PCP visit 
     
 
Yes 748 79.7 2626 78.0 
 
 
No 191 20.3 742 22.0 
 
Endocrinologist visit 
    
*  
Yes 70 7.5 328 9.7 
 
 
No 869 92.5 3040 90.3 
 
Number of Oncologists visits     *** 
 0-10 253 26.9 798 23.7  
 11-20 318 33.9 1387 41.2  
 ≥ 20 368 39.2 1183 35.1  
Availability of Oncology Treatment Centers 
    
 
Yes 632 67.3 2335 69.3 
 
 
No 307 32.7 1033 30.7 
 
Census tract education 
     
 
0-13.29% 264 28.2 915 27.2 
 
 
13.30%-22.83% 302 32.3 986 29.3 
 
 
22.84%-38.55% 203 21.7 766 22.8 
 
 
>38.55% 167 17.8 693 20.6 
 
       
...Continued       
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Table 2: Description of Elderly Women with Incident Breast Cancer and Pre-
existing Diabetes by 3-Year All-cause Mortality, SEER-Medicare 2007–2011  
Variables Dead Alive 
 
 
N % N % sig 
Census tract household income 
    
 
< $25,000 65 6.9 240 7.1 
 
 
$25,001-50,000 441 47.0 1441 42.8 
 
 
$50,001-75,000 278 29.6 1060 31.5 
 
 
>$75,000 155 16.5 627 18.6 
 
SEER region 
    
** 
 
Northeast 165 17.6 640 19.0 
 
 
South 322 34.3 958 28.4 
 
 
North-central 149 15.9 509 15.1 
 
 
West 303 32.3 1261 37.4 
 
Metropolitan status 
     
 
Metro 725 77.3 2622 77.9 
 
 
Urban 183 19.5 641 19.0 
 
 
Rural 30 3.2 102 3.0 
 
       
DCSI = Diabetes complications severity index; PCP = Primary care providers; COPD = Chronic Obstructive 
Pulmonary Disorder; SEER = Surveillance, Epidemiology, and End Results; BC = Breast cancer; DM = Diabetes 
mellitus.                    
Asterisks represent statistically significant group differences based on χ2 tests by stage of BC at diagnosis:    
*** p<0.001; ** 0.001 < p <0.01; * 0.01 < p ≤0.05 
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Table 3: Association of Diabetes Complication Severity Index with Hazard of 3 Years All-cause Mortality After 
Breast Cancer Diagnosis among Elderly women with pre-existing Diabetes Mellitus   
  
   
 
Model 1 Model 2a Model 3b 
Variables HR 95% CI Sig. HR 95% CI Sig. HR 95% CI Sig. 
DCSI 
         
 
DCSI = 0 1.00            ― 
 
1.00            ― 
 
1.00         ― 
 
 
DCSI = 1 1.21 [ 0.92, 1.58] 
 
1.33 [ 1.01, 1.74] * 1.34 [ 1.02, 1.75] *  
DCSI = 2 2.06 [ 1.70, 2.48] *** 1.67 [ 1.38, 2.03] *** 1.69 [ 1.39, 2.05] ***  
DCSI ≥ 3 3.30 [ 2.78, 3.92] *** 2.27 [ 1.89, 2.73] *** 2.24 [ 1.86, 2.70] *** 
Diabetes Medications Use in 3 Months after BC Diagnosis 
     
 
Metformin      ―             ― ― 0.75 [ 0.63, 0.89] *** 0.74 [ 0.63, 0.88] ***  
Insulin       ―             ― ― 1.55 [ 1.33, 1.80] *** 1.58 [ 1.35, 1.84] *** 
Cancer Therapy 
         
 
Had Chemotherapy      ―             ― ― 0.98 [ 0.80, 1.18] 
 
0.85 [ 0.69, 1.05] 
 
 
Had Radiation      ―             ― ― 0.69 [ 0.58, 0.83] *** 0.63 [ 0.52, 0.76] ***  
Had any Surgery      ―             ― ― 0.45 [ 0.38, 0.53] *** 0.45 [ 0.38, 0.53] *** 
Progesterone receptor status 
        
 
Positive      ―             ― ― 0.75 [ 0.61, 0.92] ** 0.74 [ 0.60, 0.92] **  
Negative      ―             ― ― 1.00            ― 
 
1.00            ― 
 
 
Borderline/Unknown      ―             ― ― 0.46 [ 0.20, 1.04] 
 
0.45 [ 0.20, 1.02] 
 
Estrogen receptor status   
         
 
Positive      ―             ― ― 0.62 [ 0.49, 0.79] *** 0.62 [ 0.49, 0.79] ***  
Negative      ―             ― ― 1.00            ― 
 
1.00            ― 
 
 
Borderline/Unknown      ―             ― ― 1.72 [ 0.73, 4.03] 
 
1.74 [ 0.74, 4.11] 
 
Number of Oncologists visits 
        
 
0-10      ―             ― ―  ―             ― ― 1.00            ― 
 
 
11-20      ―             ― ― ―             ― ― 0.98 [ 0.81, 1.19] 
 
 
≥ 20      ―             ― ― ―             ― ― 1.39 [ 1.12, 1.72] ** 
Had Endocrinologist Visit 
        
 
Yes      ―             ― ― ―             ― ― 0.74 [ 0.56, 0.98] *  
No      ―             ― ― ―             ― ― 1.00            ― 
 
           
HR = hazard ratio; CI = Confidence interval; DCSI = Diabetes complications severity index; BC = Breast cancer.     
a  Adjusted  for stage of BC at diagnosis, race, age, and comorbid conditions (asthma, COPD, dementia, 
hyperlipidemia, anxiety, and depression). 
b  Adjusted  for stage of BC at diagnosis, race, age, comorbid conditions (asthma, COPD, dementia, hyperlipidemia, 
anxiety, and depression), and SEER region.                                                                                                                                                                                                                                                                                                                                                                                                                                          
Asterisks represent statistically significant group differences compared with the reference group:                 
***p<0.001; ** 0.001 < p <0.01; * 0.01 < p<0.05 
 
 
 
 
109 
 
 
 
 
 
 
 
CHAPTER FIVE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
110 
 
DISCUSSION 
Overview  
The current study was conducted to assess the relationship of severity of pre-existing 
diabetes complications with persistence with breast cancer (BC) screening, stage of BC at 
diagnosis, and all-cause mortality of incident BC in elderly women with pre-existing diabetes 
(Figure1). To accomplish the overall goal of this study, we pursued three main aims.  
The first aim was to examine the association between the severity of diabetes 
complications and persistence with BC screening among elderly women with diabetes, 
comparing them to women with no diabetes complications. We also assessed the association of 
possible covariates with persistence with BC screening. Theses covariates include predisposing 
factors, enabling factors, need factors, health behaviors and external environmental factors. 
The second aim was to explore how the severity of diabetes complications influences the 
association between diabetes and stage of BC at diagnosis in incident BC cases with pre-existing 
diabetes. We also investigated the group differences in stage of BC at diagnosis by the cohort 
characteristics that included mammography screening, biological factors (age, race, hormone 
receptors (HR) status, and comorbid conditions), and non-biological factors (access to health 
care and community related factors).    
In the third aim, we evaluated the relationship between severity of pre-existing diabetes 
complications and all-cause mortality within three years of BC diagnosis among elderly women 
with pre-existing diabetes. In addition, we explored the association of other independent 
variables: cancer characteristics, patient-related factors, cancer treatment, and diabetes 
medications with all-cause mortality among incident BC cases with pre-existing diabetes.    
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In the first aim, we used the 5% random sample of linked Surveillance, Epidemiology, 
and End Results (SEER)-Medicare data to include elderly women with diabetes who were free of 
cancer during years 2002 to 2008. This data has been used to assess rates of cancer screening and 
to address factors associated with lower rates of cancer screening among Medicare populations 
who are free of cancer (Kagay, Quale, & Smith-Bindman, 2006; McBean & Yu, 2007; White et 
al., 2011). In the second and third aim, we used SEER-Medicare of breast cancer cases data 
which is a large national-based data of cancer-related information along with availability of 
medical claims data. The use of the SEER-Medicare data in the second aim enabled us to identify 
incident BC cases and assessing all possible risk factors and pre-existing conditions. In the third 
aim, using SEER-Medicare enabled us to assess the impact of pre-existing conditions on BC 
outcomes. Also, we linked the data to area health resources file (AHRF) and US census tract 
information to control for county level variables, such as the availability of oncology centers or 
the density of mammography facilities in areas of women residence. This cancer registry data 
that was linked with medical claims in a large population-based database, and linked to county 
level information enabled us to control for a comprehensive list of possible covariates. This 
allowed for the assessment of the independent role of the severity of pre-existing diabetes 
complications on BC screening, stage of BC at diagnosis, and all-cause mortality of incident BC.  
This is also the first study to investigate the independent role of the severity of pre-
existing diabetes complications on BC spectrum of care: prevention, diagnosis, and prognosis.  
The Main Findings  
The severity of diabetes-related complications was significantly associated with 
persistence with BC screening, stage of BC at diagnosis, and all-cause mortality within 3 years 
of BC diagnosis.  
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Both the persistence with BC screening among elderly women with diabetes and the risk 
of death after BC diagnosis in elderly women with pre-existing diabetes were significantly 
associated with diabetes complication severity index (DCSI) after controlling for all possible 
covariates. Based on our results from aim 1 and aim3, we found that there is an independent role 
of diabetes complications severity on lower persistence with BC screening and higher risk of 
mortality within 3 years of BC diagnosis among elderly women with pre-existing diabetes. Also, 
having any diabetes complication could predict lower persistence with BC screening and higher 
risk of death within 3 years after BC, and this impact is increasing as the severity of diabetes 
complications increases.  
In aim 2, the impact of diabetes complication severity on stage of BC at diagnosis was 
mostly mediated by BC screening, except the association between having a DCSI =2 and stage I 
of BC at diagnosis. Since women with more severe diabetes complications are less likely to have 
BC screening, they are more likely to be diagnosed at an advanced-stage of BC as compared to 
those without diabetes complications.  
Characteristics of the Cohorts  
For the cohorts’ size, the first study included 16,726 of elderly women with diabetes, the 
second study had 7,729 elderly women with incident BC and pre-existing diabetes, and the last 
study had 4,307 elderly women with incident BC and pre-existing diabetes. In all cohorts, the 
majority were white, lived in metro areas, had been diagnosed with early stages (0, I, or II) of BC 
at diagnosis, and had positive hormone receptor (HR) status. For other comorbid conditions, 
most all cohorts had hypertension, hyperlipidemia, and thyroid syndrome. From 38.4% to 45.8% 
of the cohorts had no diabetes complications. For visits to physicians, the majority of all cohorts 
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had primary care providers (PCP) visits, and a small proportion of women had endocrinologist 
visits.    
Other Predictors of Persistence with BC screening, Stage of BC at diagnosis, and Risk of 
Mortality  
The common variables that were significantly associated with persistence with BC 
screening, stage of BC at diagnosis, and all-cause mortality were age groups, race, having a pre-
existing chronic obstructive pulmonary disorder (COPD), dementia, and hyperlipidemia. Women 
who had pre-existing COPD and dementia were less likely to be persistent in BC screening, more 
likely to be diagnosed an advanced stage of BC, and more likely to die within three years of BC 
diagnosis. Women who had pre-existing hyperlipidemia were more likely to be persistent in BC 
screening, less likely to be diagnosed in advanced stages of BC, and less likely to die three years 
of BC diagnosis.  
For other factors, having annual PCP visits was associated with significant increase in 
persistence with BC screening, and decrease in the likelihood of being diagnosed at advanced 
stages of BC among women with pre-existing diabetes. Also, women who had thyroid syndrome 
were more likely to be persistent with BC screening and less likely to be diagnosed at advanced 
stages of BC while women who had arthritis were less likely to be persistent with BC screening 
and more likely to be diagnosed with advanced stages of BC among women with pre-existing 
diabetes. Women with positive progesterone HR status were less likely to be diagnosed at 
advanced stages of BC diagnosis and less likely to die within three years of BC diagnosis.  
Limitations 
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The study should be interpreted in the light of several limitations. For the database, 
although the SEER-Medicare data provide a population-based database of elderly population, 
this data lacked information related to mammogram screening covered by Medicare but not 
billed to Medicare. Also, this data is limited to Medicare enrollees who live in SEER areas, and 
SEER areas tend to have higher income, and have lower percentages of whites as compared to 
the U.S. population (Warren et al., 2002). Also, SEER-Medicare data lacked information, such as 
physical activity and diet which significantly impact diabetes control and cancer outcomes.   
Furthermore, in cases where women are non-users or non-persistent in receiving 
screening mammogram during the 60 months, we could not determine whether the patient had 
refused to obtain the recommended screening or the primary care physicians had not referred the 
patient.   
Also, although we controlled for many potential factors that are associated with BC stage at 
diagnosis and all-cause mortality after incident BC, data was lacking on some biological factors, 
such as obesity, family history of BC, blood glucose level, glycosylated hemoglobin A1c lab 
results, and diabetes duration which could have had residual confounding effect on the study 
outcomes. Also, exclusions of incident BC cases with missing stage of BC and others with no 
continuous enrollment in parts A, B, & D or enrollment in an HMO at any time during the study 
period may have affected the generalizability of our findings.  
Strengths 
This was the first study, to the best of the authors’ knowledge, that investigated the 
relationship of diabetes complications severity with persistence with BC screening, stage of BC 
at diagnosis, and all-cause mortality among elderly women with pre-existing diabetes. To assess 
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the severity of diabetes-related complications, we used DCSI which captures both the type and 
severity of complications while a simple count of complications does not take into account the 
severity of each complication. (Young et al., 2008). DCSI is a valid and reliable index to 
measure diabetes severity which enabled us to capture the severity of the disease and its-related 
complications, assessing its impact on study outcomes. In addition to its use as measure of 
diabetes severity, a study by Young et al. found that this index may be considered as a proxy 
measure for diabetes duration (Young et al., 2008). Young et al. found that the DCSI was highly 
correlated diabetes duration, and it attenuated the significant impact of diabetes duration on 
mortality after it was added to the analysis model (Young et al., 2008).  Because diabetes may 
remained undiagnosed for years, using DCSI as a severity measure of long- term complications 
probably demonstrate the consequences of biologic markers of diabetes duration (Harris & 
Eastman, 2000).  Moreover, in aim1, women who had any diagnostic code of any type of cancer 
were excluded to increase the probability that the identified screening mammograms were indeed 
for screening.  In aim 2 and aim3, the (SEER-Medicare) database enabled us to identify incident 
breast cancer cases and assess all possible risk factors and pre-existing conditions. In addition to 
assessing diabetes severity, the study accounted for a comprehensive list of biological factors 
(e.g. comorbid conditions and hormone receptor status) and non-biological factors (e.g. access to 
health care, and community-related factors) that may impact the associations of interest. Another 
major strength of this study is the large size of the study cohorts, and this increased the statistical 
power of the reported results. 
Conclusion & Future Research  
In short, this study suggests that severity of diabetes complications has a direct 
association with BC screening, and all cause-mortality of incident BC and has an indirect 
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association with stage of BC at diagnosis in elderly women with pre-existing diabetes (figure 2). 
The results suggest that as severity of diabetes increases, the priority of breast cancer screening 
decreases. Also, our results revealed that severity of diabetes-related complications is strongly 
associated with death even after controlling for diabetes medications, cancer treatment, 
biological characteristics of cancer, and other patient-related factors among incident BC cases. 
Management of theses complications among women with BC requires more than the treatment of 
BC and controlling blood glucose since these complications include many types of end-organ 
damage.  
Therefore, new strategies of coordination and comprehensive care from a wide variety of 
providers (e.g. endocrinologists, oncologists, and general practitioners) are needed for elderly 
women with incident BC and pre-existing diabetes complications who have complex health 
needs.    
Future research should test this association in other types of cancer. More studies are 
needed to assess whether improvement in management of diabetes complications leads to 
improvement in health outcome of cancer patients with pre-existing diabetes.  
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Figure 1: the impact of severity of pre-existing diabetes complications on breast cancer 
spectrum of care 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: The main suggested associations from the study results 
